




(12) PATENT ABRIDGMENT (11) Document No. AU-B-23533/92
 (19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 659485

- (54) Title
 IMIDAZO-FUSED ISO- AND HETEROCYCLES, PROCESS FOR THEIR PREPARATION,
 COMPOSITIONS CONTAINING THEM AND THEIR USE
- (51)⁵ International Patent Classification(s)
 C07D 409/10 C07D 235/08 C07D 471/04 C07D 487/04
 C07D 519/00 A61K 031/425
- (21) Application No. : 23533/92 (22) Application Date : 11.09.92
- (30) Priority Data
- (31) Number (32) Date (33) Country
 4130659 14.09.91 DE GERMANY
 4131325 20.09.91 DE GERMANY
- (43) Publication Date : 18.03.93
- (44) Publication Date of Accepted Application : 18.05.95
- (71) Applicant(s)
 HOECHST AKTIENGESELLSCHAFT
- (72) Inventor(s)
 HOLGER HEITSCH; ADALBERT WAGNER; HEINZ-WERNER KLEEMANN; HERMANN GERHARDS;
 BERNWARD SCHOLKENS
- (74) Attorney or Agent
 WATERMARK PATENT & TRADEMARK ATTORNEYS , Locked Bag 5, HAWTHORN VIC 3122
- (56) Prior Art Documents
 AU 78246/91 C07D 235/08
 AU 78201/91 C07D 235/08
 AU 78200/91 C07D 235/08 C07D 403/10
- (57) Claim

1. A compound of the formula II



(II)

in which the symbols have the following meaning:

- Z(1), Z(2), Z(3) and Z(4) are : 1. $-\text{CH}_2-$,
 2. $-\text{CH}=-$, or
 3. a radical defined in 2., where 1 or 2 methine
 groups are replaced by nitrogen;

.../2

- R(1) is
1. (C₁-C₁₀)-alkyl,
 2. (C₃-C₁₀)-alkenyl,
 3. (C₃-C₁₀)-alkynyl,
 4. (C₃-C₈)-cycloalkyl,
 5. benzyl or
 6. benzyl which is substituted on the phenyl by 1 or 2 identical or different radicals from the series consisting of halogen, (C₁-C₄)-alkoxy and nitro;

R(2) and R(3) are identical or different and are:

1. hydrogen,
2. hydroxyl,
3. halogen,
4. a linear or branched (C₁-C₆)-alkyl radical, unsubstituted or substituted by one or more identical or different substituents from the series consisting of halogen, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylthio and mercapto, or
5. -CO₂R(6);

- R(6) is
1. hydrogen,
 2. (C₁-C₈)-alkyl,
 3. (C₃-C₈)-cycloalkyl,
 4. phenyl,
 5. benzyl or
 6. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine;

L is (C₁-C₃)-alkanediyl;

R(12) and R(13) are identical or different and are

1. hydrogen,
2. halogen,
3. nitro,
4. (C₁-C₄)-alkyl or
5. (C₁-C₂)-alkoxy;

q is zero or 1;

A is either

1. the radical of a heterocycle having 5-10 ring atoms, which can be

.../3

mono- or bicyclic, and of which up to 9 ring atoms are carbon atoms, which radical is unsubstituted or substituted by up to 3, identical or different radicals R(14) and R(15),

or

2. a biphenyl radical which is substituted by one radical defined in R(15), 14., 15. or 20. below, and q = zero,




- R(14) is 1. (C₁-C₄)-alkyl,
2. (C₁-C₄)-alkoxy,
3. cyano,
4. amino,
5. nitro,
6. fluorine, chlorine or bromine,
7. (C₁-C₄)-heteroaryl-CH₂,
8. (C₁-C₄)-alkanoyloxy,
9. (C₁-C₄)-alkanoyl,
10. benzoyl or
11. tetrazolyl;

- R(15) is 1. (C₁-C₄)-alkyl,
2. ~~(C₆-C₁₂)-aryl~~, (C₆-C₁₂) aryl,
3. (C₁-C₃)-alkanoyloxy,
4. (C₁-C₄)-alkoxy,
5. (C₁-C₉)-heteroaryl,
6. cyano
7. nitro,
8. hydroxyl,
9. SO₃R(6),
10. chlorine, bromine,
11. CO₂R(6),
12. CO-NH-R(19),
13. CO-R(20)
14. SO₂-NR(18)-CO-NR(17)R(16),
15. SO₂-NR(18)-CO-O-R(17) or SO₂-N(CO-OR(17))₂,
16. CO-CHR(19)-CO₂H,

.../4

(10) 659485


17. (C₁-C₄)-alkyl-CO₂H,
18. NH-CO-NH-SO₂-CH₂-R(19),



23. R(14) with R(15) together are -CO-NH-SO₂;

R(16) and R(17) are identical or different and are

1. hydrogen,
2. (C₁-C₆)-alkyl,
3. (C₃-C₈)-cycloalkyl,
4. (C₆-C₁₂)-aryl,
5. (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl,
6. 2-pyrimidinyl, 1-piperidinyl, or quinuclidinyl,
7. (C₃-C₆)-alkenoyl,
8. a radical as defined in 4., 5., 6., 9., 14., 15., 16., 18., 19., or 20.,
substituted by 1 or 2 identical or different radicals from the series
~~consisting of~~ comprising hydroxyl, methoxy, nitro, cyano, CO₂R(6),
trifluoromethyl, -NR(25)R(26) and




9. (C₁-C₉)-heteroaryl-(C₁-C₃)-alkyl, where the heteroaryl moiety can be partially or completely hydrogenated,
10. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine,
11. (C₂-C₆)-alkenyl
12. (C₃-C₈)-cycloalkenyl,

.../5

• (10) 659485

13. (C₃-C₈)-cycloalkenyl-(C₁-C₃)-alkyl,
14. (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl,
15. (C₆-C₁₀)-aryl-(C₃-C₆)-alkenyl,
16. (C₁-C₉)-hetaryl-(C₃-C₆)-alkenyl,
17. (C₃-C₈)-alkynyl,
18. (C₆-C₁₀)-aryl-(C₃-C₆)-alkynyl,
19. (C₁-C₉)-hetaryl-(C₃-C₆)-alkynyl,



where R(16) cannot have the meaning of 20. (Stereocenters can be present either in the R- or in the S-configuration).

21. R(16)R(17), together with the nitrogen atom bearing them, form a hetaryl which can also be partially or completely hydrogenated;


R(18) is 1. hydrogen,

R(19) is 1. hydrogen,

2. (C₁-C₆)-alkyl,
3. (C₃-C₈)-cycloalkyl,
4. phenyl or
5. benzyl;

R(20) is 1. hydrogen,

2. (C₁-C₆)-alkyl,
3. (C₃-C₈)-cycloalkyl,
4. phenyl-(CH₂)_q,
5. OR(19),
6. NR(25)R(26) or



R(22) is CO₂R(6) or CH₂ CO₂R(6);

D is NR(23), O or CH₂;

R(23) is hydrogen, halogen, (C₁-C₄)-alkyl or (C₁-C₄)-alkoxy;

.../6

(10) 659485

R(25) and R(26) are identical or different and are

1. hydrogen,
2. (C₁-C₄)-alkyl,
3. phenyl,
4. benzyl or
5. α -methylbenzyl;

T is

1. a single bond,
2. -CO-,
3. -O-,
4. -NH CO-,
5. -O-CH₂-,

and their physiologically tolerable salts; with the proviso that if Z(1), Z(2), Z(3) and Z(4) are -CH=; A is as defined under A2. with q is zero and R(15) is SO₂NH-CO-NHR(16), R(16) cannot be (C₁-C₆)-alkyl; (C₆-C₁₂)-aryl or (C₂-C₆)-alkenyl.

**ORIGINAL
COMPLETE SPECIFICATION
STANDARD PATENT**

Application Number:

Lodged:

Invention Title:

IMIDAZO-FUSED ISO- AND HETEROCYCLES, PROCESS FOR THEIR
PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE.

The following statement is a full description of this invention, including the
best method of performing it known to :-US


Description

Imidazo-fused iso- and heterocycles, process for their preparation, compositions containing them and their use

5 EP-A 399,731, EP-A 399,732, EP-A 400,835 and EP-A 434,038 disclose imidazo-fused aromatic compounds as antagonists of angiotensin II receptors. However, none of these literature sources describe compounds which simultaneously have a cyclically substituted phenyl ring as a substituent on the nitrogen of the imidazole ring and a heterocycle fused to the imidazole ring; just as few compounds are disclosed or suggested which bear a homo-
10 aromatic compound fused to the imidazole and at the same time a biphenyl group on the nitrogen atom of the imidazole; likewise, no compounds are disclosed which bear a sulfonylurea or sulfonylurethane radical on the biphenyl group.

Imidazole derivatives have now been found which are surprisingly highly active antagonists of angiotensin II
20 receptors both in vitro and in vivo.

The invention relates to compounds of the formula



in which the symbols have the following meaning:


X is a monocyclic radical having 3, 4 or 5 ring atoms

or a bicyclic radical having 8-10 ring atoms, which radical can be completely or partially hydrogenated and in which one or more CH or CH₂ groups can be replaced by N, NH or O;

- 5 R(1) is 1. (C₁-C₁₀)-alkyl,
2. (C₃-C₁₀)-alkenyl,
3. (C₃-C₁₀)-alkynyl,
4. OR(6),
5. (C₃-C₈)-cycloalkyl,
10 6. (C₄-C₁₀)-cycloalkylalkyl,
7. (C₅-C₁₀)-cycloalkylalkenyl,
8. (C₅-C₁₀)-cycloalkylalkynyl,
9. (CH₂)_n-B-(CH₂)_n-R(7),
10. benzyl,
15 11. a radical as defined in 1., 2., 3. or 9.,
which is monosubstituted by CO₂R(6),
12. a radical as defined in 1., 2., 3. or 9., in
which 1 to all of the hydrogen atoms are
substituted by fluorine, or
20 13. the radical defined in 10. which is sub-
stituted on the phenyl by 1 or 2 identical
or different radicals from the series
comprising halogen, (C₁-C₄)-alkoxy and nitro;
- R(2), R(3), (R4) and R(5) are identical or different and
25 are
1. hydrogen, halogen, hydroxyl, cyano, nitro,
sulfo, formyl, benzoyl, (C₁-C₈)-acyl, (C₁-C₈)-
acyloxy, mercapto, carboxyl, (C₁-C₄)-alkoxy-
carbonyl,
30 2. a linear or branched, optionally substituted
alkyl, alkenyl, alkoxy or allylthio radical
containing up to 6 carbon atoms,
3. an aryl, arylalkyl or arylalkenyl radical
in which the alkyl and alkenyl substituent
35 in unbranched or branched form has up to 6
carbon atoms and the aryl substituent is a
monocyclic radical having 5 or 6 ring atoms

or condensed rings having 5 or 6 ring atoms, in which one or more hetero atoms such as O, N or S are contained and which are optionally substituted,

5



10

- R(6) is
1. hydrogen,
 2. (C₁-C₈)-alkyl,
 3. (C₃-C₈)-cycloalkyl,
 4. phenyl,
 5. benzyl or
 6. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine;

15

- R(7) is
1. hydrogen,
 2. (C₁-C₈)-alkyl,
 3. (C₃-C₈)-cycloalkyl
 4. (C₂-C₄)-alkenyl or
 5. (C₂-C₄)-alkynyl;

20

R(8) and R(9) or R(10) and R(11) are either identical or different and are

25

1. hydrogen,
2. (C₁-C₈)-alkyl or (C₁-C₈)-alkenyl, unsubstituted or substituted by halogen, hydroxyl or (C₁-C₈)-alkoxy,
3. aryl or (C₁-C₈)-alkylaryl, in which the aryl radical is monocyclic having 5 or 6 ring atoms or bicyclic having 8-10 ring atoms, optionally contains one or more hetero atoms such as O, N and S and is substituted by 1 or 2 identical or different radicals from the series comprising halogen, hydroxyl, nitro, (C₁-C₈)-alkyl, (C₁-C₈)-alkenyl, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkanoyloxy and CO₂R⁶;

30

35

R(8) and R(9) or R(10) and R(11), together with the nitrogen atom bearing them, form a 4- to 8-membered ring which is saturated or unsaturated, can contain a further hetero atom selected from the group comprising N, O and S and is unsubstituted or substituted by halogen, hydroxyl, (C₁-C₄)-alkyl, (C₁-C₄)-alkenyl, (C₁-C₄)-alkyloxy and CO₂R(6),

or

R(10) and R(11) are either identical or different and are an acyl radical of up to 6 carbon atoms or a (C₁-C₆)-alkyl or (C₆-C₁₂)-aryl radical which is optionally substituted by halogen or (C₁-C₆)-alkyl radicals;

L is (C₁-C₃)-alkanediyl;

R(12) and R(13) are identical or different and are

1. hydrogen,
2. halogen,
3. nitro,
4. (C₁-C₄)-alkyl or
5. (C₁-C₂)-alkoxy;

q is zero or 1;

A is either

1. the radical of a heterocycle having 5-10 ring atoms, which can be mono- or bicyclic, and of which up to 9 ring atoms are carbon atoms, which radical is unsubstituted or substituted by up to 6, preferably up to 3, identical or different radicals R(14) and R(15),

or

2. a biphenyl radical which is unsubstituted or substituted by up to 4, preferably up to 2, identical or different radicals R(14) and R(15), where A, however, must be substituted

by at least one radical defined in R(15)
18., 19., 28., 40. or 42. and q = zero,

R(14) is 1. halogen,

2. oxo,

5

3. nitroso,

4. nitro,

5. amino,

6. cyano,

7. hydroxyl,

10

8. (C₁-C₆)-alkyl,

9. (C₁-C₄)-alkanoyl,

10. (C₁-C₄)-alkanoyloxy,

11. CO₂R(6),

12. methanesulfonylamino,

15

13. trifluoromethanesulfonylamino,

14. -CO-NH-OR(16),


15. -SO₂-NR(17)R(18),

16. -CH₂-OR(18),


20

17. (C₁-C₄)-heteroaryl-(CH₂)_q-, preferably
1-tetrazolyl,

18. (C₇-C₁₃)-aroyl,

19. -CH₂-N 

25

20. -CH₂-C(=O)-N  or

21. (C₆-C₁₂)-aryl;

R(15) is 1. hydrogen,

2. (C₁-C₆)-alkyl,

3. (C₃-C₆)-cycloalkyl,

30

4. (C₆-C₁₂)-aryl,






5. (C₇-C₁₃)-aroyl,






6. (C₁-C₄)-alkoxy,

7. (C₁-C₄)-alkanoyloxy,

8. (C₁-C₆)-heteroaryl,

9. $\text{CO}_2\text{R}(6)$,
10. halogen,
11. cyano,
12. nitro,
13. $\text{NR}(17)\text{R}(18)$,
14. hydroxyl,
15. $-\text{CO}-\text{NH}-\text{CHR}(19)-\text{CO}_2\text{R}(6)$,
16. sulfo,
17. $-\text{SO}_3\text{R}(6)$,
18. $-\text{SO}_2-\text{NR}(18)-\text{CO}-\text{NR}(17)\text{R}(16)$,
 $-\text{SO}_2-\text{NR}(18)-\text{CO}-\text{O}-\text{R}(17)$, $-\text{SO}_2\text{N}(\text{CO}-\text{O}-\text{R}(17))_2$ or
 $-\text{SO}_2-\text{NR}(18)-\text{CS}-\text{NR}(17)\text{R}(16)$,
19. $-\text{NR}(18)-\text{CO}-\text{NR}(17)-\text{SO}_2-\text{CH}_2-\text{R}(18)$,
20. $-\text{C}(\text{CF}_3)_2\text{OH}$,
21. phosphonooxy,
22. $-\text{PO}_3\text{H}_2$,
23. $-\text{NH}-\text{PO}(\text{OH})_2$,
24. $-\text{S}(\text{O})_x\text{R}(17)$,
25. $-\text{CO}-\text{R}(20)$,
26. $-\text{CO}-\text{NR}(17)\text{R}(16)$,





39. -CO-NH-SO₂-R(6),

40. -SO₂-NH-CO-R(17),

41. the radical defined in 4., substituted by 1 or 2 identical or different radicals from the series comprising halogen, cyano, nitro, NR(17)R(18) and hydroxyl,


42. R(15) together with R(14) is -CO-NH-SO₂-;

R(16) and R(17) are identical or different and are

1. hydrogen,
2. (C₁-C₆)-alkyl,
3. (C₃-C₆)-cycloalkyl,
4. (C₆-C₁₂)-aryl, preferably phenyl,
5. (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl,
6. (C₁-C₉)-heteroaryl which can be partially or completely hydrogenated, preferably

2-pyrimidinyl, 1-piperidinyl, or quinuclidinyl,

7. (C₃-C₈)-alkenoyl,
8. a radical as defined in 4., 5., 6., 9., 14., 15., 16., 18., 19. or 20., substituted by 1 or 2 identical or different radicals from the series comprising hydroxyl, methoxy, nitro, cyano, CO₂R(6), trifluoromethyl, -NR(25)R(26) and



9. (C₁-C₈)-heteroaryl-(C₁-C₃)-alkyl, where the heteroaryl moiety can be partially or completely hydrogenated,
10. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine,
11. (C₂-C₈)-alkenyl,
12. (C₃-C₈)-cycloalkenyl,
13. (C₃-C₈)-cycloalkenyl-(C₁-C₃)-alkyl,
14. (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl,
15. (C₆-C₁₀)-aryl-(C₃-C₆)-alkenyl,
16. (C₁-C₈)-hetaryl-(C₃-C₆)-alkenyl,
17. (C₃-C₈)-alkynyl,
18. (C₆-C₁₀)-aryl-(C₃-C₆)-alkynyl,
19. (C₁-C₈)-hetaryl-(C₃-C₆)-alkynyl,

20. a radical of the formula $\begin{array}{c} \text{R(16)} \\ | \\ \text{---C---} \\ | \\ \text{OR(16)} \\ \text{O} \end{array}$

where R(16) cannot have the meaning of 20. Stereocenters can be present either in the R- or in the S-configuration.

21. R(16)R(17), together with the nitrogen atom bearing them, form a hetaryl which can also be partially or completely hydrogenated;


- R(18) is
1. hydrogen,
 2. (C₁-C₆)-alkyl,
 3. (C₃-C₈)-cycloalkyl,

- 9 -

4. (C₆-C₁₂)-aryl-(C₁-C₈)-alkyl, preferably benzyl,
5. phenyl or
6. (C₁-C₈)-heteroaryl;

- 5 R(19) is
1. hydrogen,
 2. (C₁-C₆)-alkyl,
 3. (C₃-C₈)-cycloalkyl,
 4. phenyl or
 5. benzyl;

- 10 R(20) is
1. hydrogen,
 2. (C₁-C₆)-alkyl,
 3. (C₃-C₈)-cycloalkyl,
 4. phenyl-(CH₂)_q-,
 5. OR(19),
 6. NR(25)R(26) or



R(21) is cyano, nitro or CO₂R(18);

R(22) is CO₂R(6) or CH₂CO₂R(6);

20 R(23) is hydrogen, halogen, (C₁-C₄)-alkyl or (C₁-C₄)-alkoxy;

R(24) is hydrogen, (C₁-C₄)-alkyl or phenyl;

R(25) and R(26) are identical or different and are

- 25
1. hydrogen,
 2. (C₁-C₄)-alkyl,
 3. phenyl,
 4. benzyl or
 5. α-methylbenzyl;

D is NR(23), O or CH₂;

B is O, NR(18) or S;

- 30 T is
1. a single bond,
 2. -CO-,
 3. -CH₂-,
 4. -O-,
 5. -S-,
 6. -NR(28)-,
- 35

- 10 -

- 5 7. $-\text{CO}-\text{NR}(28)-$,
 8. $-\text{NR}(28)-\text{CO}-$,
 9. $-\text{O}-\text{CH}_2-$,
 10. $-\text{CH}_2-\text{O}-$,
 11. $-\text{S}-\text{CH}_2-$,
 12. $-\text{CH}_2-\text{S}-$,
 13. $-\text{NH}-\text{CR}(27)\text{R}(29)-$,
 14. $-\text{NR}(28)-\text{SO}_2-$,
 15. $-\text{SO}_2-\text{NR}(28)-$,
 10 16. $-\text{CR}(27)\text{R}(29)-\text{NH}-$,
 17. $-\text{CH}=\text{CH}-$,
 18. $-\text{CF}=\text{CF}-$,
 19. $-\text{CH}=\text{CF}-$,
 20. $-\text{CF}-\text{CH}-$,
 15 21. $-\text{CH}_2-\text{CH}_2-$,
 22. $-\text{CF}_2-\text{CF}_2-$,
 23. $-\text{CH}(\text{OR})(6)-$,
 24. $-\text{CH}(\text{OCOR}(19))-$,
 20 25. $-\text{C}-$
 \parallel
 $\text{NR}(30)$ or
 26. $\begin{array}{c} -\text{C}- \\ / \quad \backslash \\ \text{R}(31)\text{O} \quad \text{OR}(32) \end{array}$

- 25 R(27) and R(29) are identical or different and are
 hydrogen, (C_1-C_5) -alkyl, phenyl, allyl or benzyl;
 R(28) is hydrogen, (C_1-C_6) -alkyl, benzyl or allyl;
 R(30) is 1. $\text{NR}(27)\text{R}(28)$,
 2. ureido,
 30 3. thioureido,
 4. toluene-4-sulfonyl or
 5. benzenesulfonylamino;

- R(31) and R(32) are identical or different and are
 (C_1-C_4) -alkyl or together are $-(\text{CH}_2)_q-$;
 35 Q is CH_2 , NH, O or S;
 n is an integer from 1 to 5;
 m is an integer from 0 to 3;
 o is an integer from 1 to 10;
 r is zero, 1 or 2

and their physiologically tolerable salts.

Alkyl, alkenyl and alkynyl can be straight-chain or branched. The same applies to radicals derived from these, such as alkanoyl or alkoxy.

- 5 Cycloalkyl is also understood as meaning alkyl-substituted rings.

(C₆-C₁₂)-aryl is, for example, phenyl, naphthyl or biphenyl, preferably phenyl. The same applies to radicals derived from these, such as aroyl or aralkyl.

- 10 (C₁-C₉)-heteroaryl is in particular understood as meaning radicals which are derived from phenyl or naphthyl, in which one or more CH groups are replaced by N and/or in which at least two adjacent CH groups are replaced (with the formation of a 5-membered aromatic ring) by S, NH or
15 O. Furthermore, one or both atoms of the condensation site of bicyclic radicals (such as in indoliziny) can also be a nitrogen atom.


- These radicals are, for example, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
20 oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyradiazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl.

- The fused heterobicycle AH, from which the radical A is derived, is in particular understood as meaning a bicyclic ring system having 8 to 10 ring atoms of which up to 9 ring atoms are carbon atoms, in which two adjacent atoms are together constituents of both rings. One or both of these rings are formally derived from benzene in
25 which one or more CH groups are replaced by N, O⁺ and S⁺ and/or in which two adjacent CH groups are replaced (with the formation of a 5-membered aromatic ring) by S, NH or
30 O.

A, for example, is a radical of benzothiophene, benzofuran, indole, isoindole, indazole, benzimidazole, quinoline, isoquinoline, phthalazine, quinoxaline, quinazoline, cinnoline, benzothiazole, benzothiazole-1,1-dioxide, coumarin, chroman, benzoxazole, benzisothiazole, benzodiazine, benzotriazole, benzotriazine, benzoxazine, imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazothiazole, pyrazolopyridine, thienopyridine and pyrrolopyrimidine. Said heterobicycle AH can also be partially or completely hydrogenated. Preferably, however, one ring of AH remains aromatic, a benzo-fused heterobicycle AH being particularly preferred.

In the case of S-containing and/or partially saturated radicals, the bicycle can also be, for example, oxo-substituted as is the case in the radical of benzo-1,2,3-triazinone.

The linkage of A takes place by the isocyclic or by the heterocyclic moiety, in the case where $q = 0$ via an alkanediyl bridge L and in the case where $q = 1$ via a single bond to give the



An iso- or heterocycle XH_2 , from which the mono- or bicyclic radical X is derived, is understood as meaning, for example, a radical of cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, benzene, naphthalene, furan, thiophene, pyrrole, pyridine, pyridazine, pyrimidine, piperidine, piperazine, morpholine, indole, indazole, oxazole, isoxazole, quinoline, isoquinoline, benzothiophene, benzofuran, benzothiazole, benzoxazole, imidazopyridine, imidazopyrimidine and furopyridine.

Halogen is fluorine, chlorine, bromine or iodine.

Physiologically tolerable salts of compounds of the

6. benzyl which is substituted as described above;

R(2) and R(3) are identical or different and are:

1. hydrogen,
2. hydroxyl,
3. halogen,
4. a linear or branched (C₁-C₆)-alkyl radical, unsubstituted or substituted by one or more identical or different substituents from the series comprising halogen, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylthio and mercapto,
5. -CO₂R(6);

T is a single bond, -O-, -CO-, -NHCO- or -OCH₂- and the other radicals and variables are as defined above.

Particularly preferred compounds of the formula II are those in which

R(1) is (C₁-C₇)-alkyl, (C₃-C₇)-alkenyl or (C₃-C₇)-alkynyl;




R(6) is hydrogen or (C₁-C₄)-alkyl;

R(12) and R(13) are identical or different and are hydrogen or (C₁-C₄)-alkyl;

- R(14) is
1. (C₁-C₄)-alkyl,
 2. (C₁-C₄)-alkoxy,
 3. cyano,
 4. amino,
 5. nitro,
 6. fluorine, chlorine or bromine,
 7. (C₁-C₄)-heteroaryl-CH₂,
 8. (C₁-C₄)-alkanoyloxy,
 9. (C₁-C₄)-alkanoyl,
 10. benzoyl or
 11. tetrazolyl;

- R(15) is
1. (C₁-C₄)-alkyl,
 2. (C₆-C₁₂)-aryl,

3. (C₁-C₃)-alkanoyloxy,
4. (C₁-C₄)-alkoxy,
5. (C₁-C₆)-heteroaryl, preferably 5-tetrazolyl,
6. cyano,
7. nitro,
8. hydroxyl,
9. SO₃R(6),
10. chlorine, bromine,
11. CO₂R(6),
12. CO-NH-R(19),
13. CO-R(20),
14. SO₂-NR(18)-CO-NR(17)R(16),
15. SO₂NR(18)-CO-O-R(17) or SO₂N(CO-OR(17))₂,
16. CO-CHR(19)-CO₂H,
17. (C₁-C₄)-alkyl-CO₂H,
18. NH-CO-NH-SO₂-CH₂-R(19),



23. R(14) with R(15) together are -CO-NH-SO₂;

L is -CH₂-;


R(18) is hydrogen;

R(25) and R(26), independently of one another, are hydrogen or (C₁-C₄)-alkyl, and their physiologically tolerable salts.


The invention also relates to a process for the preparation of compounds of the formula I , which comprises alkylating compounds of the formula III



16



in which Z(1), Z(2), Z(3), Z(4), R(1), R(2) and R(3) are as defined above,
with compounds of the formula IV



- 5 in which L, q, R(12), R(13) and A are as defined above and U is a leaving group, optionally removing temporarily introduced protective groups again and optionally converting the compounds of the formula I obtained into their physiologically tolerable salts.

Suitable leaving groups U are preferably nucleofugic groups (cf. Angew. Chem. 72 (1960)) such as halogen, o-toluenesulfonate, mesylate or triflate.

Processes for the preparation of the precursors of the formula III are disclosed, inter alia, in US 4,880,804, DE 3,911,603, EP-A-399,731, EP-A-399,732, EP-A-400,835, EP-A-400,974, EP-A-415,886, EP-A-420,237, EP-A-425,921 and EP-A-434,038.

- 15 For the alkylation of the compounds of the formula III, for example, appropriate benzyl halides, tosylates, mesylates or triflates or appropriate alkyl halides, tosylates, mesylates or triflates are suitable.

These compounds are prepared in a manner known as per se, for example halogenation of the corresponding methyl precursors. For this purpose, N-bromosuccinimide is



preferably employed, see, for example, J.Org. Chem. 44, 4733 (1979) and Helv. Chim. Acta 62, 2661 (1979).

5 The synthesis of the benzimidazole, benzothiophene, imidazopyridine and imidazopyrimidine derivatives having a CH₃ group on the ring is carried out, inter alia, according to R.P. Dickson et al. in J.Med. Chem. 29, 1637 (1986), E. Abignente et al. in J.Heterocyclic Chem. 26, 1875 (1989), A. Koubsack et al. in J.Org. Chem. 41, 3399 (1976) and according to F. Santer et al. in Mh. Chem. 99, 10 715 (1968).

The biphenyl derivatives can be synthesized, for example, starting from arylboronic acid derivatives by coupling with substituted aryl halides using transition metal catalysts, in particular palladium. Appropriate reactions are described by R.B. Miller et al. (Organometallics 15 1984, 3, 1261) or by A. Zuzuki et al. (Synthetic Commun. 11 (7), 513 (1981)).

20 The sulfonylurethane derivatives of the formula (I) can be obtained from appropriate sulfonamides of the formula (I) by reaction with chlorocarbonic acid esters, or by reacting with dimethyl dicarbonate and bases such as, for example, potassium carbonate in inert solvents at temperatures up to the boiling point of the appropriate solvent.

25 The sulfonylurea derivatives of the formula (I) can be prepared, as desired, either from the appropriate sulfonamides of the formula (I) by reaction with isocyanates or with 2,2,2-trichloroacetamide derivatives of a suitable amine in inert, high-boiling solvents such as, for example, DMSO or from sulfonyl urethanes of the formula 30 (I) by action of the appropriate amine in an inert, high-boiling solvent such as, for example, toluene at temperatures up to the boiling point of the respective solvent.

If necessary, the sulfonamide radical can be prepared starting from an amino group by means of Meerwein

rearrangement. For this purpose, the hydrochloride of the amine is first diazotized and then reacted with sulfur dioxide in glacial acetic acid in the presence of a copper catalyst. Subsequent action of ammonia leads to the sulfonamido group.

Alkylation is carried out in an analogous manner by processes known in principle.

The imidazo-fused derivatives of the formula III are metalated, for example, in the presence of a base. Preferred bases are metal hydrides of the formula MH such as lithium hydride, sodium hydride or potassium hydride in, for example, DMF or DMSO as the solvent or metal alkoxides of the formula MOR, where R is methyl, ethyl or t-butyl, and the reaction is carried out in the appropriate alcohol, DMF or DMSO. The salts of the imidazo derivatives thus formed are dissolved in an aprotic solvent such as DMF or DMSO and treated with a suitable amount of alkylating reagent.

An alternative possibility for deprotonation of the imidazole derivatives is, for example, reaction with potassium carbonate in DMF or DMSO.

The reactions are carried out for about 1 to 10 hours at temperatures below room temperature up to the boiling point of the reaction mixture, preferably between +20°C and the boiling point of the reaction mixture.

The compounds of the formula I according to the invention have antagonistic action on angiotensin II receptors and can therefore be used for the treatment of angiotensin II-dependent hypertension. Possibilities of use furthermore exist in cardiac insufficiency, cardioprotection, myocardial infarct, cardiac hypertrophy, arteriosclerosis, nephropathy, kidney failure and cardiovascular diseases of the brain such as transitory ischemic attacks and cerebral apoplexy.

Renin is a proteolytic enzyme of the aspartylprotease class, which is secreted into the blood circulation from the juxtaglomerular cells of the kidney as a result of various stimuli (volume depletion, sodium deficiency, β -receptor stimulation). There it cleaves the decapeptide angiotensin I from the angiotensinogen secreted by the liver. This is converted into angiotensin II by the "angiotensin converting enzyme" (ACE). Angiotensin II plays an essential role in blood pressure regulation, as it directly increases the blood pressure by vascular contraction. Additionally, it stimulates the secretion of aldosterone from the adrenal gland and in this manner increases the extracellular fluid volume by means of the inhibition of sodium excretion, which in turn contributes to an increase in blood pressure.

Post-receptor effects are, inter alia, stimulation of phosphoinositol conversion (Ca^{2+} release), activation of protein kinase C and facilitation of AMP-dependent hormone receptors.

The affinity of the compounds of the formula I for the angiotensin II receptor can be determined by measurement of ^{125}I -angiotensin II or ^3H -angiotensin II displacement from receptors on Zona glomerulosa membranes of bovine adrenal glands. To do this, the prepared membranes are suspended in buffer at pH 7.4. In order to prevent the degradation of the radioligand during incubation, aprotinin, a peptidase inhibitor, is added. About 14000 cpm of a tracer having a specific activity of 74 TBq/mmol (commercially available from Amersham Buchler) and an amount of receptor protein which binds 50% of the tracer are additionally used. The reaction is started by addition of 50 μl of membrane suspension to a mixture of 100 μl of buffer + aprotinin, 50 μl of buffer with or without angiotensin II or receptor antagonist and 50 μl of tracer. After an incubation period of 60 minutes at 25°C, bound and free radioligand are separated by a filtration assay using Whatmann® GFIC filters on a

Skatron® cell collector.

Non-specific binding is prevented by treatment of the filter with 0.3% polyethyleneimine pH = 10 (Sigma, No. 3143). By measurement of the radioactivity in a gamma scintillation counter, the strength of the displacement of the radioligand of the receptor is determined. The IC_{50} values, which denote the concentration of the inhibitor necessary to displace 50% of the ligand, are determined according to Chem. et al. J. Theor. Biol. 59, 253 (1970). For the compounds of the formula (I) they are in the range from 1×10^{-4} - 1×10^{-8} M.

Alternatively, the affinity of the compounds of the formula I for the angiotensin II receptor can be determined by measurement of the ^{125}I angiotensin II or 3H angiotensin II displacement of receptor preparations from various organs (liver, lung, adrenal gland, brain etc.).

For this purpose, the prepared membranes are suspended in an incubation buffer (20 mM tris, pH 7.4, containing 135 mM NaCl, 10 mM KCl, 10 mM $MgCl_2$, 5 mM glucose, 0.2% bovine serum albumin and the protease inhibitors PMSF 0.3 mM and bacitracin 0.1 mM) and incubated at $25^\circ C$ for 90 min together with the radioactively labeled angiotensin II and various concentrations of the compounds to be tested. Bound and free radioligand are then separated by filtration through micro glass fiber filters (GF51, Schleicher & Schüll) on a cell collector (SKATRON).

By measurement of the receptor-bound radioactivity on the filters by means of a beta spectrometer or gamma spectrometer, the degree of displacement of the radioligand from the receptor by the test compounds is determined. The potency of the displacement of the radioligand from the receptor by the test compounds is given by the IC_{50} , i.e. the concentration of the inhibitor which displaces 50% of the bound radioligand from the receptor. The calculation of the IC_{50} values is carried out by means of PC software

(LIGAND, G.A. McPherson 1985, Elsevier-BIOSOFT, 68 Hills Road, Cambridge CB 21LA, UK). The IC_{50} values measured for compounds of the formula (I) are in the range from 1×10^{-5} to 1×10^{-11} M.

- 5 To determine the antagonistic action of the compounds of the formula (I) in vivo, their inhibiting effect on the angiotensin II-induced blood pressure increase in emedulated Sprague-Dawley rats (Möllegard, Denmark) can be measured. The blood pressure is measured in the carotid
- 10 artery. I.v. administration is carried out in the penis vein. After preparation of the animal and a waiting time of 20 minutes to stabilize the hemodynamic parameters, 3 successive injections of 10, 30 and 100 ng of angiotensin II in 0.1 ml of aqueous solution are administered at
- 15 5 minute intervals. The compounds of the formula (I) are dissolved in distilled water, if necessary with addition of 10% strength ethanol and/or bases ($pH < 10$) or acids ($pH > 3$), and administered intravenously in doses of 1-300 $\mu g/kg$ or intraduodenally in doses of 5-1000 $\mu g/kg$.
- 20 In the case of intraduodenal administration, the angiotensin II injection takes places after 20, 40 and 60 minutes, while in the case of intravenous administration the pressor response sequence takes place at 10 minute intervals.
- 25 The compounds of the formula (I) are intravenously active, in particular in the range from 1 to 300 $\mu g/kg$ or intraduodenally active, in particular in the range from 5 to 300 $\mu g/kg$.

- 30 The invention also relates to pharmaceutical compositions consisting of a compound of the formula I and other active compounds, such as, for example, diuretics or non-steroidal anti-inflammatory active compounds. The compounds of the formula I can also be used as diagnostics for the renin-angiotensin system.

- 35 Pharmaceutical preparations contain an effective amount of the active compound of the formula I and possibly

other active compounds together with an inorganic or organic pharmaceutically utilizable excipient. Administration can be carried out intranasally, intravenously, subcutaneously or perorally. The dosage of the active compound depends on the warm-blooded species, the body weight and age and on the manner of administration.

The pharmaceutical preparations of the present invention are prepared in a dissolving, mixing, granulating or coating process known per se.

For an oral administration form, the active compounds are mixed with the additives customary for this purpose such as excipients, stabilizers or inert diluents and brought by a customary method into suitable administration forms, such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions. Inert carriers which can be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose, magnesium stearyl fumarate or starch, in particular corn starch. In this case, the preparation can result either as dry or moist granules. Suitable oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil and cod liver oil.

For subcutaneous or intravenous administration, the active compounds or their physiologically tolerable salts, if desired with the substances customary for this purpose such as solubilizers, emulsifiers or other auxiliaries, are made into solutions, suspensions or emulsions. Possible solvents are, for example: water, physiological saline solution or alcohols, for example ethanol, propanediol or glycerol, and in addition also sugar solutions such as glucose or mannitol solutions or alternatively a mixture of the various solvents mentioned.

According to the abovementioned process, for example, the

following IC₅₀ values were determined for the compounds of Examples 1, 2, 3, 15, 19, 27, 31 and 51:

	Example	IC ₅₀ [nM]
	1	78
5	2	65
	3	149
	15	0.8
	19	0.74
	27	1.1
10	31	0.48
	51	1.8

List of abbreviations:

	DCI	desorption-chemical ionization
	DMF	N,N-dimethylformamide
15	EA	ethyl acetate
	FAB	fast atom bombardment
	h	hour(s)
	Hep	n-heptane
	Min	minute(s)
20	NBS	N-bromosuccinimide
	RT	room temperature

Example 1

2-n-Butyl-1-[(2-carboxy-3-chlorobenzo[b]thiophen-6-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

- 25 a) 2-Carboxy-6-nitrobenzamide
30 g (0.155 mol) of 3-nitrophthalic anhydride are introduced in portions into 180 ml of conc. ammonium solution and the resulting solution is heated at 100°C with stirring for 45 min. The mixture is evaporated in a rotary evaporator and co-distilled twice with toluene, and the residue is dried in a high vacuum. It is stirred with EA, and the beige precipitate is filtered off with suction and dried in vacuo over P₂O₅. 31.8 g of the title compound are obtained.
- 35 Melting point: 188°C

R_f (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 1:1) = 0.3
MS (DCI): 211 (M+H)

b) 2-Amino-3-nitrobenzoic acid

31 g (0.147 mol) of the compound from Example 1 a) are dissolved in 50 ml of 4N sodium hydroxide solution and 100 ml of water, 150 ml of sodium hypochlorite solution (excess on KI-starch paper) are added and the solution obtained is heated at 100°C for 60 min. After completion of the reaction, it is cooled, treated with 250 ml of satd. Na_2CO_3 solution and 400 ml of satd. KH_2PO_4 solution, the pH of the solution is adjusted to 3 with 4N HCl/conc. HCl and the product is extracted 3 times using 500 ml of EA each time. After drying over MgSO_4 , concentrating and stirring with diisopropyl ether, 18 g of the title compound are obtained.

Melting point: 188-194°C

R_f (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 1:1) = 0.7
MS (DCI): 183 (M+H)

c) Methyl 2-amino-3-nitrobenzoate

18 g (99 mmol) of the compound from Example 1 b) are stirred under reflux in 200 ml of methanol with 20 ml of thionyl chloride for 48 h. The reaction solution is evaporated in a rotary evaporator, the residue is taken up in 400 ml of satd. Na_2CO_3 solution, the solution is extracted 3 times with EA, and the combined organic phases are washed with dilute Na_2CO_3 solution and satd. NaCl solution, dried over Na_2SO_4 and concentrated. Chromatography on SiO_2 with EA/Hep 9:1 and 7:3 yields 11.5 g of the title compound.

Melting point: 86-88°C

R_f (SiO_2 , EA/Hep 1:1) = 0.5
MS (DCI): 197 (M+H)

d) methyl 2-[N-(n-pentanoyl)amino]-3-nitrobenzoate

7 g (35.5 mmol) of the compound from Example 1 c) are stirred at 110°C for 1 h in 50 ml of valeryl chloride. The mixture is concentrated to dryness, the residue is

treated with active carbon in ether for 30 min and filtered, the filtrate is concentrated and the residue is purified by chromatography on SiO₂ using EA/Hep 2:8. 5.8 g of the title compound result.

5 Melting point: 66-69°C

R_f (SiO₂, EA/Hep 1:1) = 0.4

MS (DCI): 281 (M+H)

e) 6-Bromomethyl-3-chloro-2-methoxycarbonylbenzo-
[b]thiophene

10 2.5 g (10.4 mmol) of 3-chloro-2-methoxycarbonyl-6-methyl-
benzo[b]thiophene (prepared according to J.Org. Chem. 41,
3399 (1976)) are boiled under reflux in 150 ml of chloro-
benzene with 1.87 g of NBS and 420 mg of dibenzoyl
15 peroxide for 5 h. After distilling off the chlorobenzene
in a rotary evaporator, the residue obtained is taken up
in EA, and the EA solution is washed with satd. NaHCO₃
solution, 10% strength Na₂SO₄ solution and satd. NaCl
solution, dried over Na₂SO₄ and concentrated. Chroma-
tography on SiO₂ using EA/Hep 1:20 yields 2.28 g of the
20 title compound.

Melting point: 143-145°C

R_f (SiO₂, EA/Hep 1:20) = 0.3, - MS (DCI): 319, 321 (M+H)

f) Methyl 2-[N-(n-pentanoyl)-((3-chloro-2-methoxy-
carbonylbenzo[b]thiophen-6-yl)methyl)]amino-
25 3-nitrobenzoate

800 mg (2.86 mmol) of the compound from Example 1 d) are
dissolved in 5 ml of abs. DMF, the solution is treated
with 395 mg of K₂CO₃ and the mixture is stirred at room
temperature for 10 min. A solution of 913 mg of the
30 compound from Example 1 e) in 20 ml of abs. DMF is added
dropwise and the reaction solution is stirred overnight
at room temperature. The DMF is then stripped off in
vacuo, the residue is taken up in EA, and the EA phase is
washed with H₂O, dilute, saturated NaHCO₃ and saturated
35 NaCl solution, dried over Na₂SO₄ and concentrated. Chroma-
tography on SiO₂ using EA/Hep 1:2 yields 860 mg of the
title compound.

R_f (SiO₂, EA/Hep 1:2) = 0.3
MS(FAB): 519 (M+H)

g) Methyl 2-n-butyl-1-[(3-chloro-2-methoxycarbonyl-
benzo[b]thiophen-6-yl)methyl]-1H-benzimidazole-
7-carboxylate

450 mg (0.85 mmol) of the compound from Example 1 f) are
hydrogenated in 50 ml of ethanol for 1 h in the presence
of Raney nickel. The catalyst is filtered off, the
filtrate is concentrated to dryness and the resulting
residue is stirred at 50°C for 30 min in 10 ml of EA/iso-
propanol (1:1) and 10 ml of an HCl-saturated EA solution.
After concentration and crystallization from methanol,
190 mg of the title compound result.

Melting point: 167-170°C (dec.)

R_f (SiO₂, CH₂Cl₂/MeOH/NH₄OH 49/1/0.1) = 0.3
MS (DCI): 471 (M+H)

h) 2-n-Butyl-1-[(2-carboxy-3-chlorobenzo[b]-
thiophen-6-yl)methyl]-1H-benzimidazole-
7-carboxylic acid

185 mg (0.39 mmol) of the compound from Example 1 g) are
dissolved in 10 ml of ethanol, 1 ml of H₂O and 1 ml of
conc. NaOH are added and the solution obtained is stirred
at room temperature for 3 h. The EtOH is stripped off in
vacuo, the aqueous solution is adjusted to a pH of 3 with
glacial acetic acid and the deposited precipitate is
filtered off with suction. After drying in a high vacuum,
100 mg of the title compound are obtained in the form of
white crystals.

Melting point: > 260°C

R_f (SiO₂, EA/MeOH 2/1) = 0.18
MS (FAB): 443 (M+H)

Example 2

2-n-Butyl-1-[(3-carboxy-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-1H-benzimidazole-7-carboxylic acid

a) Ethyl 2-benzoyl-2-bromoacetate

5 25 ml (0.144 mol) of ethyl benzoyl acetate are dissolved in 50 ml of CCl_4 , 8.5 ml of bromine are added dropwise at 5°C and the brown solution is stirred at 5°C for 1 h, at room temperature for 3 h and at 60°C for 2 h. It is concentrated to dryness, the residue is taken up in EA, the EA solution is washed with 10% strength Na_2SO_3 solution and satd. NaCl solution, dried over MgSO_4 and concentrated, and the residue is dried in a high vacuum. 38 g of the title compound result as a red oil.

R_f (SiO_2 , EA/Hep 1/6) = 0.28

15 MS (DCI): 271, 273 (M+H)

b) Ethyl 7-methyl-2-phenylimidazo[1,2-a]pyridine-3-carboxylate

38 g (0.14 mol) of the compound from Example 2 a) and 15.2 g of 2-amino-4-methylpyridine are stirred in ethanol for 8 h under reflux. The mixture is concentrated to dryness, the residue is treated with satd. Na_2CO_3 solution and extracted several times with EA, and the combined organic phases are washed with satd. NaCl , dried over Na_2SO_4 and concentrated. Chromatography on SiO_2 using EA/Hep 2:1 yields 12.2 g of the title compound.

R_f (SiO_2 , EA/Hep 2:1) = 0.3

25 MS (DCI): 281 (M+H)

c) Ethyl 7-bromomethyl-2-phenylimidazo[1,2-a]pyridine-3-carboxylate

30 3 g (10.7 mmol) of the compound from Example 2 b) are brominated with 1.27 g of NBS and 150 mg of benzoyl peroxide by the process given in Example 1 e). 1.2 g of the title compound result.

R_f (SiO_2 , EA/Hep 1/2) = 0.2

35 MS (DCI): 359, 361 (M+H)

d) Methyl 2-[N-(n-pentanoyl)-(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]amino-3-nitrobenzoate

800 mg (2.85 mmol) of the compound from Example 1 d),
5 1.03 g of the compound from Example 2 c) and 400 mg of K_2CO_3 are reacted by the process mentioned in Example 1 f). 520 mg of the title compound result.

R_f (SiO_2 , EA/Hep 1:1) = 0.2

MS (FAB): 559 (M+H)

10 e) Methyl 2-n-butyl-1-[(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-1H-benzimidazole-7-carboxylate

400 mg (0.71 mmol) of the compound from Example 2 d) are
15 reacted by the process mentioned in Example 1 g). After precipitation from methanol using diethyl ether, 250 mg of the title compound result.

Melting point: 217-220°C (dec.)

R_f (SiO_2 , EA/Hep 9/1) = 0.5

MS (DCI): 511 (M+H)

20 f) 2-n-Butyl-1-[(3-carboxy-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-1H-benzimidazole-7-carboxylic acid

230 mg (0.45 mmol) of the compound from Example 1 e) are
25 hydrolyzed by the process given in Example 1 h). 117 mg of the title compound in the form of white crystals result.

Melting point: 202-204°C

R_f (SiO_2 , EA/MeOH 2/1) = 0.1

MS (FAB): 469 (M+H)

30 Example 3

2-n-Butyl-1-[(3-carboxy-2-phenylimidazo[1,2-a]pyrimidin-7-yl)methyl]-1H-benzimidazole-7-carboxylic acid

a) Ethyl 7-methyl-2-phenylimidazo[1,2-a]pyrimidine-3-carboxylate

35 The title compound is prepared by the process described

in Example 2 b) from the compound of Example 2 a) and 2-amino-4-methylpyrimidine.

$$R_2 (\text{SiO}_2, \text{EA/Hep } 2:1) = 0.2$$

MS (DCI): 282 (M+H):

5 b) Ethyl 7-bromomethyl-2-phenylimidazo[1,2-a]-
pyrimidine-3-carboxylate

This compound is prepared by the process mentioned in Example 2 c); from 2g(7.11 mmol) of the compound of example 3 a), 510 mg of the title compound result.

10 R_f (SiO₂, EA/Hep 1:2) = 0.2

MS (FAB): 360, 362 (M+H)

c) Methyl 2-[N-(n-pentanoyl)-(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyrimidin-7-yl)methyl]-amino-3-nitrobenzoate

15 This compound is prepared by the process of Example 1f). From 435 mg (1.55 mmol) of the compound from Example 1d) and 558 mg of the compound from Example 3b), 550 mg of the title compound are obtained.

$$R, (\text{SiO}_2, \text{EA/Hep } 2:1) = 0.2$$

20 MS (DCI): 560 (M+H)

d) Methyl 2-n-butyl-1-[(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyrimidin-7-yl)methyl]-1H-benzimidazole-7-carboxylate

This compound is prepared by the process mentioned in Example 1g); from 380 mg (0.68 mmol) of the compound of Example 3 c), 102 mg of the title compound result as a slightly beige, crystalline residue.

Melting point: 185-187°C

$$R_f (\text{SiO}_2, \text{EA/Hep } 1:1) = 0.2$$

30 MS (FAB): 512 (M+H)

e) 2-n-Butyl-1-[(3-carboxy-2-phenylimidazo[1,2-a]-pyrimidin-7-yl)methyl]-1H-benzimidazole-7-carboxylic acid

This compound is prepared by the process mentioned in

Example 1 h). From 45 mg (0.09 mmol) of the compound of Example 3 d), 31 mg of the title compound are obtained.

Melting point: > 260°C

R_f (SiO₂, EA/MeOH) = 0.1

5 MS (FAB): 470 (M+H)

Example 4

2-n-Butyl-3-[(2-carboxy-3-chlorobenzo[b]thiophen-6-yl)-methyl]-3H-imidazo[4,5-b]pyridine

a) 2-n-Butyl-3H-imidazo[4,5-b]pyridine

10 10 g (91.6 mmol) of 2,3-diaminopyridine and 27.4 g of valeric acid are stirred at 170°C for 18 h. After completion of the reaction, the mixture is diluted with 100 ml of CH₂Cl₂, washed with saturated NaHCO₃ solution, water and saturated NaCl solution, dried over Na₂SO₄ and concentrated. Chromatography on SiO₂ using EA/Hep 20:1 yields 9.7 g of the title compound.

15 Melting point: 103°C

R_f (SiO₂, EA/MeOH 20:1) = 0.3

MS (DCI): 176 (M+H)

20 b) 2-n-Butyl-3-[(3-chloro-2-methoxycarbonylbenzo[b]thiophen-6-yl)methyl]-3H-imidazo[4,5-b]pyridine

25 300 mg (0.94 mmol) of the compound from Example 1 e) and 175 mg of the compound from Example 4 a) are stirred at room temperature for 8 h with 552 mg of K₂CO₃ in 10 ml of DMF. The mixture is concentrated to dryness, the residue is taken up in EA, and the EA solution is washed with H₂O, dilute KHSO₄ solution, saturated NaHCO₃ solution and saturated NaCl solution, dried over Na₂SO₄ and concentrated. Chromatography on SiO₂ using EA/Hep 1:1 yields 130 mg of the title compound as a slightly yellow powder.

30 Melting point: 127-129°C

R_f (SiO₂, EA/Hep 1:1) = 0.2

MS (DCI): 414 (M+H)

c) 2-n-Butyl-3-[(2-carboxy-3-chlorobenzo[b]-thiophen-6-yl)methyl]-3H-imidazo[4,5-b]pyridine
117 mg (0.28 mmol) of the compound from Example 4b) are reacted by the process mentioned in Example 1 h). 107 mg of the title compound result as a white powder.
Melting point: > 260°C
 R_f (SiO₂, EA/MeOH 2:1) = 0.3
MS (FAB): 400 (M+H)

Example 5

2-n-Butyl-3-[(3-carboxy-2-phenylimidazo[1-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

a) 2-n-Butyl-3-[(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

The title compound is prepared by the process mentioned in Example 4 b) from the compounds of Examples 2 c) and 4 a).
MS (DCI): 454 (M+H)

b) 2-n-Butyl-3-[(3-carboxy-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

The title compound is prepared by the process given in Example 1 h) from the compound of Example 5 a).
MS (FAB): 426 (M+H)

Example 6

2-n-Butyl-3-[(3-carboxy-2-phenylimidazo[1,2-a]pyrimidin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

a) 2-n-Butyl-3-[(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyrimidin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

This compound is prepared from the compounds of Examples 3 b) and 4 a) by the process of Example 4 b).
MS (DCI): 455 (M+H)

b) 2-n-Butyl-3-[(3-carboxy-2-phenylimidazo[1,2-a]-pyrimidin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

The title compound results from the compound of Example 6 a) by the reaction described in Example 1 h).

5 MS (FAB): 427 (M+H)

Example 7

2-n-Butyl-3-[2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)-imidazo[4,5-b]pyridinyl]-3H-imidazo[4,5-b]pyridine

10 a) 2-(4-Methylphenyl)imidazo[4,5-a]pyridine
8.6 g (91.4 mmol) of 2-aminopyridine and 7.7 g (45.7 mmol) of chloromethyl p-tolyl ketone (prepared according to Chem. Lett., 1990, 1125-1128) are stirred at 130°C for 45 min. The reaction solution is then diluted with CH₂Cl₂, washed with water and saturated NaCl solution, dried over MgSO₄ and concentrated. Chromatography on SiO₂ using EA/Hep 4:1 → 1:1 yields 6.8 g of the title compound.

15 Melting point: 142-144°C

R_f (SiO₂, EA/Hep 1:1) = 0.2

20 MS (DCI): 209 (M+H)

b) 3-Formyl-2-(4-methylphenyl)imidazo[4,5-a]pyridine

25 21 ml (0.27 mol) of DMF are treated with 3.6 ml of POCl₃ in 60 ml of CH₂Cl₂ at 0°C; the reaction solution is stirred at room temperature for 30 min and a solution of 6.8 g (32.7 mmol) of the compound from Example 7 a) is added dropwise at 0°C. After stirring for 2 h at 60°C, the mixture is concentrated, the residue is treated with a solution of 20 g of NaOH in 200 ml of H₂O and stirred under reflux for 1 h, and the precipitate which deposits after cooling in an ice bath is filtered off with suction. Recrystallization from ethanol yields 5.5 g of the title compound.

30 Melting point: 168-171°C

35 R_f (SiO₂, EA/Hep 8:2) = 0.4

MS (DCI): 237 (M+H)

c) 3-Hydroximino-2-(4-methylphenyl)imidazo[4,5-a]-pyridine

2 g (8.47 mmol) of the compound of Example 7 b) are treated in 130 ml of methanol with a solution of 883 mg of hydroxylamine hydrochloride and 1.04 g of sodium acetate in 65 ml of water. The reaction solution is stirred at room temperature for 5 h and under reflux for 1 h. The methanol is stripped off in the rotary evaporator, then the residue is diluted with water and the precipitate which deposits after cooling is filtered off with suction. After drying over P_2O_5 in a high vacuum, 2.04 g of the title compound result.

Melting point: 202-206°C

R_f (SiO_2 , EA/Hep 1:1) = 0.3

MS (DCI): 252 (M+H)

d) 3-Cyano-2-(4-methylphenyl)imidazo[4,5-a]pyridine
2.1 g (9.0 mmol) of the compound from Example 7 c) are introduced in portions, with ice-cooling and stirring, into 45 ml of thionyl chloride and the reaction solution is stirred at room temperature for 45 min. The thionyl chloride is distilled off twice from toluene, the residue is taken up in EA, and the EA solution is washed with satd. Na_2CO_3 and satd. NaCl solution, dried over $MgSO_4$ and concentrated. Recrystallization from diisopropyl ether/EA yields 1.9 g of the title compound.

Melting point: 138-144°C

R_f (SiO_2 , EA/Hep 1:1) = 0.2

MS (DCI): 234 (M+H)

e) 2-(3-Bromomethylphenyl)-3-cyanoimidazo[4,5-a]-pyridine

This compound is prepared by the process mentioned in Example 1 e). From 1.7 g of the compound of Example 7 d), 1.73 g of the title compound result.

Melting point: 182-186°C

R_f (SiO_2 , EA/Hep 1:1) = 0.2

MS (DCI): 312/314 (M+H)

f) 2-n-Butyl-3-[3-cyano-2-(4-methylphenyl)-imidazo-
[4,5-a]pyridinyl]-3H-imidazo[4,5-b]pyridine

The title compound is prepared from the compounds of
Examples 4 a) and 7 e) by the process mentioned in
Example 4 b).

MS (DCI): 407 (M+H)

g) 2-n-Butyl-3-[2-(4-methylphenyl)-3-(1H-tetrazol-
5-yl)imidazo[4,5-b]pyridinyl]-3H-imidazo[4,5-b]-
pyridine

210 mg (0.51 mmol) of the compound from Example 7 f) are
stirred under reflux in 5 ml of toluene with 308 mg of
trimethyltin azide for 3 days. The reaction solution is
diluted with 4 ml of ether and, after addition of 7 ml of
saturated KF solution and 0.2 ml of HBF₄ solution (50%
strength), stirred at room temperature for 2 days. The
mixture is diluted with EA and filtered, and the organic
phase of the filtrate is separated off, washed with H₂O
and saturated NaCl solution, dried over Na₂SO₄ and concen-
trated. Chromatography on SiO₂ using EA/MeOH 3:1 yields
110 mg of the title compound.

MS (FAB): 450 (M+H)

Example 8

2-n-Butyl-1-[2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)-
imidazo[4,5-a]pyridinyl]-1H-benzimidazole-7-carboxylic
acid

a) Methyl 2-[N-(n-pentanoyl)-(3-cyano-2-(4-methyl-
phenyl)imidazo[4,5-a]pyridinyl)amino-3-nitro-
benzoate

This compound is prepared from the compounds of Examples
1 d) and 7 e) by the process given in Example 1 f). In
this process, from 730 mg (2.34 mmol) of the compound
from Example 7 e) and 655 mg (2.34 mmol) of the compound
from Example 1 d), 988 mg of the title compound result.

Melting point: 128-131°C

R_f (SiO₂, EA/Hep 8:2) = 0.3

MS (DCI): 512 (M+H)

- b) Methyl 2-n-Butyl-1-[3-cyano-2-(4-methylphenyl)-imidazo[4,5-a]pyridinyl]-1H-benzimidazole-7-carboxylate

The title compound is prepared from the compound of Example 8 a) by the process of Example 1 g).

R_f (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5) = 0.2

MS (DCI): 464 (M+H)

- c) Methyl 2-n-butyl-1-[2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)imidazo[4,5-a]pyridinyl]-1H-benzimidazole-7-carboxylate

157 mg (0.34 mmol) of the compound from Example 8 b) are reacted by the process mentioned in Example 7 g); 88 mg of the title compound result.

Melting point: 120-155°C

R_f (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 8:2) = 0.3

MS (FAB): 507 (M+H)

- d) 2-n-Butyl-1-[2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)imidazo[4,5-a]pyridinyl]-1H-benzimidazole 7-carboxylic acid

The title compound is prepared from the compound of Example 8b) by the process mentioned in Example 1 h).

R_f (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}(\text{AcOH}/\text{H}_2\text{O}$ 20:15:2:4) = 0.8

MS (FAB): 493 (M+H)

Example 9

5,7-Dimethyl-2-ethyl-3-(2-carboxy-3-chlorobenzo[b]thiophen-6-yl)-methyl]-3H-imidazo[4,5-b]pyridine

- a) 5,7-Dimethyl-2-ethyl-3-[(3-chloro-2-methoxycarbonylbenzo[b]thiophen-6-yl)methyl]-3H-imidazo[4,5-b]pyridine

500 mg (2.8 mmol) of 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine (disclosed in EP-A 400,974) are treated under argon in 10 ml of abs. DMF with 165 mg of NaH (50% strength), 900 mg (2.8 mmol) of the compound from Example 4 b) are added to the reaction solution after 30 min and the mixture is stirred at room temperature for 2 h. The

reaction solution is treated with water and extracted with EA, and the combined EA extracts are washed with water and satd. NaCl solution, dried over MgSO₄ and concentrated. Chromatography on SiO₂ using EA/MeOH 15:1 yields 700 mg of the title compound.

R_f (SiO₂, EA/MeOH 15:1) = 0.3

MS (DCI): 414 (M+H)

b) 5,7-Dimethyl-2-ethyl-3-[(2-carboxy-3-chloro-benzo[b]thiophen-6-yl)methyl]-3H-imidazo[4,5-b]pyridine

680 mg (1.64 mmol) of the compound from Example 9 a) are reacted by the process mentioned in Example 1 h). 570 mg of the title compound result.

MS (DCI): 400 (M+H)

Example 10

5,7-Dimethyl-2-ethyl-3-[(3-carboxy-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

a) 5,7-Dimethyl-2-ethyl-3-[(3-ethoxycarbonyl-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

This compound is prepared from 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine analogously to the process given in Example 9 a) (prepared according to EP-A 400,974) and the compound from Example 2 c). From 280 mg (0.78 mmol) of the compound from Example 2 c), 160 mg of the title compound result.

R_f (SiO₂, EA) = 0.2

MS (FAB): 454 (M+H)

b) 5,7-Dimethyl-2-ethyl-3-[(3-carboxy-2-phenylimidazo[1,2-a]pyridin-7-yl)methyl]-3H-imidazo[4,5-b]pyridine

The title compound is prepared from the compound of Example 10 b) by the process mentioned in Example 1 h).

MS (FAB): 426 (M+H)

Example 11

5,7-Dimethyl-2-ethyl-3-[(2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)imidazo[4,5-a]pyridinyl)-3H-imidazo[4,5]-pyridine

- 5 a) 5,7-Dimethyl-2-ethyl-3-[3-cyano-2-(4-methylphenyl)imidazo[4,5-a]pyridinyl)-3H-imidazo[4,5]pyridine

The title compound is prepared from 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine (prepared according to EP-A 400,974) and the compound from Example 7 e).
10 MS (DCI): 407 (M+H)

- b) 5,7-Dimethyl-2-ethyl-3-[(2-(4-methylphenyl)-3-(1H-tetrazol-5-yl)imidazo[4,5-a]pyridinyl)-3H-imidazo[4,5-b]pyridine

15 The title compound is prepared from the compound of Example 11 a) by the process mentioned in Example 7 g).
MS(FAB): 450 (M+H)

Example 12

3-[(2'-Aminoethylphenyl)carbonylaminosulfonylbiphenyl-4-yl)methyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine
20

- a) Sulfonamidobromobenzene

51.6 g (0.3 mol) of o-bromoaniline are added under an argon atmosphere to a solution of 100 ml of conc. HCl and 30 ml of glacial acetic acid, a solution of 22.4 g of sodium nitrite in 30 ml of water is added dropwise at -10°C and the reaction solution is stirred at -5°C for 60 min. The solution obtained is added dropwise to an SO₂-saturated solution of 7 g of CuCl₂·2H₂O and 0.5 g of CuCl in 300 ml of glacial acetic acid. After stirring at room temperature for 60 min, the mixture is poured into an ice/water mixture and extracted with ether, and the ether extracts are washed with satd. NaHCO₃ solution and water, dried over MgSO₄ and concentrated. The 67.8 g of sulfonyl chloride compound obtained are treated with 300 ml of conc. ammonia with cooling in 500 ml of
25
30
35

acetone. After stripping off the acetone, the resulting suspension is diluted with water, and the white crystals which deposit are filtered off with suction, washed with H₂O and dried in a high vacuum. The title compound is employed without further purification in the following reaction.

b) 2,N,N-Dimethylaminoformylsulfonamidobromobenzene 0.236 mol of the compound from Example 12 a) is stirred at room temperature for 2 h with 40 ml of N,N-dimethylformamide dimethyl acetal in 150 ml of abs. DMF. The reaction solution is poured into 200 ml of 5% strength NaHSO₄ solution/ice (1:1), and the precipitate which deposits is filtered off with suction, washed with H₂O and dried in vacuo. 67 g of the title compound are obtained.

R_f (SiO₂, EA/Hep 1:1) = 0.1
MS (DCI): 291/293 (M+H)

c) 4'-Methylbiphenyl-2-N,N-dimethylaminoformylsulfonamide

To 11 g (37.9 mmol) of the compound from Example 12 b), 1 g of triphenylphosphine, and 8 g of Na₂CO₃ in 150 ml of toluene and 40 ml of H₂O, first 420 mg of Pd(OAc)₂ and then 5.66 g (41.9 mmol) of tolylboronic acid in 100 ml of ethanol are added under argon. The mixture is now heated to boiling for 4 h, then concentrated and taken up in 500 ml of EA and 500 ml of H₂O. The resulting precipitate is filtered off and characterized as the title compound. The EA phase is separated off, dried over Na₂SO₄ and concentrated. Chromatography on SiO₂ using EA yields a further amount of the title compound; total yield: 7.6 g.
R_f (SiO₂, EA/Hep 1:1) = 0.2
MS (DCI): 303 (M+H)

d) 4'-Bromomethylbiphenyl-2-N,N-dimethylaminoformylsulfonamide

The title compound is prepared from the compound 12 c) by the process of Example 1 e). In this process, 1.2 g of

the title compound result from 3.8 g (13.5 mmol) of the compound 12 c).

R_f (SiO₂, EA/Hep 2:1) = 0.2

MS (DCI): 381/383 (M+H)

- 5 e) 5,7-Dimethyl-3-[(2'-N,N-dimethylaminoformyl-sulfonamidobiphenyl-4-yl)methyl]-2-ethyl-3H-imidazo[4,5-b]pyridine

10 The title compound is prepared from the compound of Example 12 d) and 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine by the process of Example 9 a). 1.1 g of the title compound is obtained from 3.2 g of the compound 12 d).

R_f (SiO₂, EA/MeOH 10:1) = 0.2

MS (FAB): 476 (M+H)

- 15 f) 5,7-Dimethyl-2-ethyl-3-[(2'-sulfonamidobiphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine

0.6 g (1.26 mmol) of the compound from Example 12 e) is boiled under reflux in 20 ml of ethanol with 10 ml of conc. HCl solution for 45 min. The ethanol is removed in vacuo, and the residue is neutralized with saturated NaHCO₃ solution, adjusted to pH ~ 5-6 with NaHSO₄ solution and extracted with EA. The EA phase is dried (Na₂SO₄) and concentrated, 380 mg of the title compound being obtained.

25 R_f (SiO₂, EA/Hep 5:1) = 0.5

MS (FAB): 421 (M+H)

- g) 5,7-Dimethyl-2-ethyl-3-[(2'-ethoxycarbonylamino-sulfonylbiphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine

30 0.52 g (1.2 mmol) of the compound from Example 12 f) and 340 mg of K₂CO₃ are heated under reflux under argon for 3 h with 266 mg (2.4 mmol) of ethyl chloroformate in 10 ml of dry DMF. After cooling to room temperature, the mixture is treated with 10% NaHSO₄ and extracted with EA, and the organic phase is dried over MgSO₄. Concentration and chromatography on SiO₂ using EA as the eluent yield 250 mg of the title compound.

R_f (SiO₂, EA) = 0.2
MS (FAB): 493 (M+H)

h) 3-[(2'-(Aminoethylphenyl)carbonylaminosulfonyl-
biphenyl-4-yl)methyl]-5,7-dimethyl-2-ethyl-3H-
imidazo[4,5-b]pyridine

80 mg (0.16 mmol) of the compound from Example 12 g) and
50 µl of phenylethylamine are boiled under reflux in 5 ml
of abs. toluene under argon for 1.5 h. After concen-
tration and chromatography on SiO₂ using EA/MeOH 10:1,
70 mg of the title compound result after freeze-drying as
an amorphous powder.

R_f (SiO₂, EA/MeOH 10:1) = 0.4
MS (FAB): 568 (M+H)

Example 13

3-[(2'-Aminomethylcyclohexyl)carbonylaminosulfonyl-
biphenyl-4-yl)methyl]-5,7-dimethyl-2-ethyl-3H-imidazo-
[4,5-b]pyridine

The title compound is prepared by the process of Example
12 h) from the compound of Example 12 g) and cyclohexyl-
methylamine; from 80 mg (0.16 mmol) of Example 12 g),
90 mg of the title compound results after freeze-drying
as an amorphous solid.

R_f (SiO₂, EA) = 0.3
MS (FAB): 560 (M+H)

Example 14

3-[(2'-Diallylamino)carbonylaminosulfonylbiphenyl-4-yl)m-
ethyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine

The title compound is prepared by the process of Example
12 h) from the compound of Example 12 g) and diallyl-
amine. 60 mg of the title compound result from 80 mg
(0.16 mmol) of Example 12 g) as an amorphous solid.

R_f (SiO₂, EA/MeOH 10:1) = 0.2
MS (FAB): 544 (M+H)

Example 15

3-[(2'-N,N-Diallyloxycarbonyl)aminosulfonylbiphenyl-4-yl)methyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]-pyridine

5 100 mg (0.23 mmol) of the compound from Example 12 f) are heated to boiling for 45 min in 10 ml of abs. DMF under argon with 66 mg (0.46 mmol) of K_2CO_3 and 57 mg (0.46 mmol) of allyl chloroformate. After concentrating, taking up in EA, washing the EA phase with 10% strength

10 Na_2HSO_4 solution, drying ($MgSO_4$) and chromatography on SiO_2 using EA, 70 mg of the title compound result after freeze-drying.

R_f (SiO_2 , EA) = 0.6

MS (FAB): 589 (M+H)

15 Example 16

3-[(2'-(N,N-Dibenzoyloxycarbonyl)aminosulfonylbiphenyl-4-yl)methyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]-pyridine

20 This compound is prepared by the process of Example 15 from the compound of Example 12 f) and benzyl chloroformate. From 100 mg (0.23 mmol) of the compound 12 f), 70 mg of the title compound result.

R_f (SiO_2 , EA) = 0.2

MS (FAB): 689 (M+H)

25 Example 17

3-[(2'-(Cyclohexylmethoxycarbonyl)aminosulfonylbiphenyl-4-yl)methyl]-5,7-dimethyl-2-ethylimidazo[4,5-b]pyridine

30 The title compound is prepared from the compound of Example 12 f) and cyclohexylmethyl chloroformate by the process of Example 15, amide and ester being employed, however, in an equimolar ratio.

R_f (SiO_2 , methyl tert-butyl ether) = 0.2

MS (FAB): 561 (M+H)

Example 18

5,7-Dimethyl-2-ethyl-3-(2'-(ethyloxycarbonyl)amino-sulfonylbiphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine

5 The title compound results from the compound of Example 12 f) and ethyl chloroformate by the process of Example 17.

R_f (SiO₂, EA) = 0.2

MS (FAB): 493 (M+H)

Example 19

10 2-n-Butyl-1-[(2'-ethoxycarbonylamino sulfonylbiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid

a) Methyl 2-[N-(n-pentanoyl)-((2'-N,N-dimethyl-amino formylsulfonamidobiphenyl-4-yl)methyl)]amino-3-nitrobenzoate

15 7.9 g (28.2 mmol) of the compound from Example 1d) are stirred at room temperature for 24 h with 10.7 g (28.2 mmol) of the compound from Example 12d) and 11.7 g (84.6 mmol) of K₂CO₃ in 200 ml of abs. DMF. The mixture is then concentrated to dryness, the residue is taken up in
20 EA, and the EA solution is washed 3 x with H₂O, 1 x with KHSO₄ solution (25% strength), 1 x with saturated NaHCO₃ solution and 1 x with saturated NaCl solution, dried over MgSO₄ and concentrated. The oily residue yields 7.9 g of the title compound after crystallization from
25 EA/diisopropyl ether. Chromatography of the concentrated mother liquor on SiO₂ using n-heptane/EA (2:3) yielded a further 2.54 g of the title compound.

Melting point: 148-152°C

R_f (SiO₂, n-heptane/EA 2:8) = 0.33

30 MS(FAB): 581 (M+H)

b) Methyl 2-[N-(n-pentanoyl)-((2'-N,N-dimethyl-aminoformylsulfonamidobiphenyl-4-yl)methyl)]amino-3-aminobenzoate

35 10.4 g (17.9 mmol) of the compound from Example 19a) are hydrogenated in 800 ml of methanol for 3h in the presence

of Raney nickel. The catalyst is filtered off, the filtrate is concentrated to dryness and the residue is dried in a high vacuum. 9.9 g of the title compound result as an amorphous foam.

5 $R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH } 95:5) = 0.3$
MS(FAB): 551 (M+H)

c) Methyl 2-n-butyl-1-[(2'-sulfonamidobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate

9.8 g (17.8 mmol) of the compound from Example 19h) are stirred under reflux for 3h with 90 ml of concentrated hydrochloric acid in 180 ml of methanol. The solvent is evaporated, the remaining solution is adjusted to pH ~ 5-6 with 6N NaOH solution, the aqueous solution is extracted 3 x with CH_2Cl_2 , and the combined organic phases are washed with saturated NaCl solution and dried over MgSO_4 . Recrystallization from EA yielded 8.16 g of the title compound in the form of white crystals.

Melting point: 192-195°C

20 $R_f(\text{SiO}_2, \text{EA}/n\text{-heptane } 8:2) = 0.38$
MS(FAB) = 478 (M+H)

Alternatively, the title compound also results by this process from the compound from Example 19a). In this case, 60 mg of the desired compound are obtained from 100 mg (0.19 mmol) of the compound from 19a).

25 d) Methyl 2-n-butyl-1-[(2'-dimethylaminoformylsulfonamidobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate

150 mg (0.18 mmol) of the compound from Example 19b) are allowed to stand at room temperature over night with 10 ml of an HCl-saturated EA solution in 10 ml of isopropanol/EA (1:1) under argon. The mixture is concentrated, the residue is taken up in CH_2Cl_2 , and the CH_2Cl_2 phase is washed with saturated Na_2CO_3 solution, water and saturated NaCl solution and dried over MgSO_4 . Concentration and drying in a high vacuum yield 138 mg of the title compound as an amorphous foam.

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH } 95:5) = 0.5$

MS(FAB): 533 (M+H)

e) Methyl 2-n-butyl-1-[(2'-ethoxycarbonylamino-
sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-
carboxylate

3.25 g (6.81 mmol) of the compound from Example 19c) and
170 mg (1.36 mmol) of DMAP are treated in 12 ml of
absolute pyridine under argon at 0°C with 1.53 g
(13.6 mmol) of K-tert-butyrate and, after stirring for
10 minutes at the same temperature, with 0.65 ml
(6.81 mmol) of ethyl chloroformate. The mixture is
stirred over night at room temperature. The solution is
then adjusted with a 25% strength KHSO_4 solution with ice-
cooling until it gives an acidic reaction and extracted
several times with EA. The combined organic phases are
washed with saturated NaCl solution, dried over MgSO_4 and
concentrated. Chromatography on SiO_2 using $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3$
(9:1:0.1) yielded 1.8 g of the title compound as an
amorphous foam.

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc } 9:1:0.2) = 0.71$

MS(FAB): 550 (M+H)

f) Methyl 2-n-butyl-1-[(2'-ethoxycarbonylamino-
sulfonylbiphenyl-4-yl)methyl]-1H-benzimidazole-7-
carboxylic acid

The preparation of the title compound from the compound
from Example 19e) is carried out by the process given in
Example 1h).

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc } 9:1:0.2) = 0.64$

MS(FAB): 536 (M+H)

Example 20

2-n-Butyl-1-[(2'-n-propylaminocarbonylamino-sulfonyl-
biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid

a) Methyl 2-n-butyl-1-[(2'-n-propylaminocarbonyl-
aminosulfonylbiphenyl-4-yl)methyl]-1H-benzimid-
azole-7-carboxylate

100 mg (0.21 mmol) of the compound from Example 19c) are boiled under reflux in 8 ml of absolute acetone with 90 mg (0.6 mmol) of K_2CO_3 in 24 μ l (0.25 mmol) of n-propyl isocyanate for 2h. After cooling, the solution is adjusted to pH ~ 1 by addition of 2N HCl and extracted several times with CH_2Cl_2 . The combined organic phases are washed 1 x with H_2O and 1 x with saturated NaCl solution, dried over $MgSO_4$ and concentrated. Recrystallization from EA yields 107 mg of the title compound

Melting point: 150-152°C

$R_f(SiO_2, CH_2Cl_2/MeOH/NH_3, 9:1:0.2) = 0.24$

MS(FAB): 563 (M+H)

b) Methyl 2-n-butyl-1-[(2'-n-propylaminocarbonylaminosulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

The title compound is prepared from the compound from Example 20a) by the process mentioned in Example 1h). 30 mg of the desired compound are obtained from 38 mg (0.07 mmol) of 20a) as an amorphous foam.

$R_f(SiO_2, CH_2Cl_2/MeOH/ACOH, 9:1:0.2) = 0.2$

MS(FAB): 549 (M+H)

Example 21

2-n-Butyl-1-[(2'-isopropylaminocarbonylaminosulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

206 mg (0.38 mmol) of the compound from Example 19e) are reacted at 80°C in an autoclave for 8h with 5 ml of isopropylamine in 50 ml of toluene. The reaction solution is concentrated and the residue is chromatographed on SiO_2 using $CH_2Cl_2/MeOH$ (95:5). 38 mg of the title compound result as an amorphous foam.

$R_f(SiO_2, CH_2Cl_2/MeOH/ACOH, 9:1:0.2) = 0.35$

MS(FAB): 549 (M+H)

Example 22

2-n-Butyl-1-[(2'-allylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

- 5 a) Methyl 2-n-butyl-1-[(2'-allylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylate

The title compound is prepared from the compound from Example 19c) by the process of Example 20a) using allyl isocyanate instead of n-propyl isocyanate. 136 mg of the title compound result from 150 mg (0.31 mmol) of 19c).

10 Melting point: 142-145°C

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3, 9:1:0.2) = 0.19$

MS(FAB): 561 (M+H)

- 15 b) 2-n-Butyl-1-[(2'-allylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

The preparation of this compound was carried out by the process of Example 1h) and yielded 73 mg of the title compound from 123 mg (0.22 mmol) of the compound from 22a).

20 Melting point: 220°C

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{ACOH}, 9:1:0.2) = 0.35$

MS(FAB): 547 (M+H)

Example 23:

- 25 2-n-Butyl-1-[(2'-ethylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylic acid

- a) Methyl-2-n-butyl-1-[(2'-ethylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylate

30 The title compound is prepared from the compound from Example 19c) by reaction with ethyl isocyanate by the process of Example 20a).

Melting point: 182°C

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3, 9:1:0.2) = 0.22$

- 35 MS(FAB): 549 (M+H)

b) 2-n-Butyl-1-[(2'-ethylaminocarbonylamino-
sulfonylbiphenyl-4-yl)-methyl]-1H-benzimidazole-7-
carboxylic acid

This compound results from the compound from 23a) by the
process of Example 1h).

Melting point: > 220°C

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc } 9:1:0.2) = 0.35$

MS(FAB): 535 (M+H)

Example 24

2-n-Butyl-1-[(2'-cyclopropylmethylaminocarbonylamino-
sulfonylbiphenyl-4-yl)methyl]-1H-benzimidazole-7-car-
boxylic acid

a) Methyl 2-n-butyl-1-[(2'-cyclopropylmethylamino-
carbonylamino-sulfonylbiphenyl-4-yl)methyl]-1H-
benzimidazole-7-carboxylate

139 mg (0.29 mmol) of the compound from Example 19c) are
stirred at 80°C for 30 minutes with 35 mg (0.88 mmol) of
powdered NaOH and 67 mg (0.32 mmol) of 2,2,2-trichloro-
N-cyclopropylmethylacetamide (prepared from cyclopropyl-
methylamine and trichloroacetyl chloride) in 2 ml of
absolute DMSO under argon. The reaction solution is
poured onto ice and acidified with 2N HCl, and the
precipitate which deposits is filtered off with suction.
After recrystallization from EA, 69 mg of the title
compound result.

Melting point: 158-161°C

$R_f(\text{SiO}_2, \text{n-heptane}/\text{EA } 2:8) = 0.23$

MS(FAB): 575 (M+H)

b) 2-n-Butyl-1-[(2'-cyclopropylmethylaminocar-
bonylamino-sulfonylbiphenyl-4-yl)methyl]-1H-
benzimidazole-7-carboxylic acid

The title compound is prepared from the compound of
Example 24a) by the process mentioned in Example 1h).

Melting point: 234-236°C

$R_f(\text{SiO}_2, \text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc } 9:1:0.2) = 0.28$

MS(FAB): 561 (M+H)

Example 25

2-n-Butyl-3-[(2'-ethoxycarbonylaminosulfonylbiphenyl-4-yl)methyl]-3H-imidazo-[4,5-b]/[5,4-b]-pyridine

- 5 a) 2-n-Butyl-3-[(2'-N,N-dimethylaminoformylsulfonamidobiphenyl-4-yl)methyl]-3H-imidazo-[4,5-b]/[5,4-b]-pyridine

10 The title compound is prepared from the compounds from Examples 4a) and 12d) by the process described in Example 4b). Purification was carried out by chromatography on SiO_2 using EA/MeOH 20:1 as the eluent and crystallization from EA/diisopropyl ether.

Melting point: 205-211°C

$R_f(\text{SiO}_2, \text{EA/MeOH } 20:1) = 0.15$

MS(FAB): 476 (M+H)

- 15 b) 2-n-Butyl-3-[(2'-sulfonamidobiphenyl-4-yl)-methyl]-3H-imidazo[4,5-b]/[5,4-b]-pyridine

This compound is prepared from the compound from 25a) by the process of Example 19c) and chromatography on SiO_2 using EA/MeOH 20:1 as the eluent.

20 $R_f(\text{SiO}_2, \text{EA/MeOH } 20:1) = 0.39$

MS(FAB): 421 (M+H)

- c) 2-n-Butyl-3-[(2'-ethoxycarbonylaminosulfonylbiphenyl-4-yl)methyl]-3H-imidazo-[4,5-b]/[5,4-b]pyridine

25 1 g (2.38 mmol) of the compound from Example 25b) is heated under reflux for 6h with 1 g of activated (high vacuum drying at 150°C for 3h) molecular sieve 4 Å, 0.66 g of K_2CO_3 and 232 μl of ethyl chloroformate in 25 ml of absolute dimethoxyethane under argon. After cooling,
30 the mixture is treated with 100 ml of 10% strength KH_2PO_4 solution (pH ~ 4), extracted 3 x with EA, and the combined EA extracts are dried over Na_2SO_4 and concentrated. Chromatography on SiO_2 (EA/MeOH 20:1) yields 0.5 g of the title compound.

35 Melting point: 172°C

$R_f(\text{SiO}_2, \text{EA/MeOH } 20:1) = 0.3$

MS(FAB): 493 (M+H)

Example 26

2-n-Butyl-3-[(2'-isopropylaminocarbonylamino-sulfonyl-biphenyl-4-yl)-methyl]-3H-imidazo[4,5-b]/[5,4-b]pyridine

5 The title compound results from 100 mg (0.2 mmol) of the compound from Example 25c) after boiling under reflux for 3h with 209 μ l (2.44 mmol) of isopropylamine in 5 ml of toluene, concentration and chromatography on SiO₂ (EA) in a yield of 45 mg.

10 Melting point: 113-114°C

R_f (SiO₂, EA/MeOH 20:1) = 0.36

MS(FAB): 506 (M+H)

Example 27

15 2-n-Butyl-3-[(2'-allylaminocarbonylamino-sulfonylbiphenyl-4-yl)-methyl]-3H-imidazo-[4,5-b]/[5,4-b]pyridine

The title compound results from the reaction of the compound from Example 25b) with allyl isocyanate analogously to the process described in Example 20a).

Melting point: 121°C

20 R_f (SiO₂, EA/MeOH 20:1) = 0.26

MS(FAB): 504 (M+H)

Example 28

2-n-Butyl-3-[(2'-n-propylaminocarbonylamino-sulfonyl-biphenyl-4-yl)-methyl]-3H-imidazo-[4,5-b]/[5,4-b]pyridine

25 150 mg (0.3 mmol) of the compound from Example 25c) are boiled under reflux for 3h with 295 μ l (3.6 mmol) of n-propylamine in 5 ml of toluene. The mixture is concentrated and the residue is chromatographed on SiO₂ (EA). 90 mg of the title compound were obtained.

30 Melting point: 137-138°C

R_f (SiO₂, EA) = 0.2

MS(FAB): 506 (M+H)

Example 29

2-n-Butyl-3-[(2'-benzyloxycarbonylaminosulfonylbiphenyl-4-yl)methyl]-3H-imidazole-[4,5-b]/[5,4-b]pyridine

5 The title compound is prepared from the compound from Example 25b) and benzyl chloroformate by the process described in Example 25c).

Melting point: 85°C

$R_f(\text{SiO}_2, \text{EA/MeOH } 20:1) = 0.29$

MS(FAB): 555 (M+H)

10 Example 30

2-Ethyl-7-methyl-3-[(2'-n-propylaminocarbonylaminosulfonylbiphenyl-4-yl)methyl]-imidazo-[4,5-b]-pyridine

a) 2-Ethyl-7-methyl-3H-imidazo[4,5-b]pyridine
10 g (65.3 mmol) of 2-amino-4-methyl-3-nitropyridine are
15 hydrogenated in 40 ml of tetrahydrofuran and 40 ml of methanol in the presence of Raney nickel. The catalyst is filtered off, the solvent is removed, the residue is treated with ethanolic HCl solution and the precipitated
20 2,3-diamino-4-methylpyridine hydrochloride is filtered off with suction. 7 g of this hydrochloride are dissolved in 57 g of polyphosphoric acid (from 28.5 g of P_2O_5 and 28.5 g of H_3PO_4 (85% strength)) and treated with 1.26 ml of propionic acid, and the solution is stirred at 100°C
25 for 2h. After cooling, it is poured into ice-water, rendered alkaline by addition of Na_2CO_3 and extracted several times with EA. The combined EA phases are washed with saturated NaCl solution, dried over Na_2SO_4 and concentrated and the residue is chromatographed on SiO_2 (EA/MeOH 5:1). 4.2 g of the title compound result.
30 $R_f(\text{SiO}_2, \text{EA/MeOH } 5:1) = 0.4$
MS(DCl): 162 (M+H)

b) 3-[(2'-N,N-dimethylaminoformylsulfonamidobiphenyl-4-yl)methyl]-2-ethyl-7-methyl-imidazo[4,5-b]pyridine

3.1 g (19.26 mmol) of the compound from Example 30a) and
5 9.15 g (19.26 mmol) of the compound from Example 12d)
(75% strength) are stirred over night at room temperature
in 200 ml of absolute DMF in the presence of 2.6 g
(19.6 mmol) of K_2CO_3 . The solvent is then removed, the
residue is taken up in CH_2Cl_2 , and the CH_2Cl_2 solution is
10 washed with H_2O , dried over Na_2SO_4 and concentrated.
Chromatography on SiO_2 (EA/MeOH 20:1) yields 2.8 g of the
title compound.

Melting point: 168-170°C

R_f (EA/MeOH 20:1) = 0.13

15 MS(FAB): 462 (M+H)

c) 2-Ethyl-7-methyl-3-[(2'-sulfonamidobiphenyl-4-yl)methyl]-imidazo[4,5-b]pyridine

2.8 g (6.06 mmol) of the compound from Example 30b) are
converted into the title compound (2.2 g) by the process
20 mentioned in Example 19c).

Melting point: 211-212°C

R_f (SiO_2 , EA/MeOH) = 0.35

MS(FAB): 407 (M+H)

d) 2-Ethyl-7-methyl-3-[(2'-n-propylaminocarbonyl-aminosulfonylbiphenyl-4-yl)methyl]-imidazo[4,5-b]pyridine

The title compound is prepared from the compound from
Example 30c) and n-propyl isocyanate by the process of
Example 20a). 43 mg of the desired product result from
30 70 mg (0.172 mmol) of compound 30c).

Melting point: 215-220°C

R_f (SiO_2 , EA/MeOH 20:1) = 0.36

MS(FAB): 492 (M+H)

Example 31

2-Ethyl-3-[(2'-ethylaminocarbonylaminosulfonylbiphenyl-4-yl)methyl]-7-methyl-imidazo[4,5-b]pyridine

5 The title compound is prepared from the compound of Example 30c) and ethyl isocyanate by the process of Example 20a).

Melting point: 240-245°C

$R_f(\text{SiO}_2, \text{EA}) = 0.14$

MS(FAB): 478 (M+H)

10 Example 32

3-[(2'-allylamino carbonylamino sulfonylbiphenyl-4-yl)-methyl]-2-ethyl-7-methyl-imidazo[4,5-b]pyridine

15 The preparation of the title compound is carried out by reaction of the compound from Example 30c) and allyl isocyanate by the process of Example 20a).

Melting point: 216-219°C

$R_f(\text{SiO}_2, \text{EA}) = 0.13$

MS(FAB): 490 (M+H)

Example 33

20 2-Ethyl-3-[(2'-methoxycarbonylamino sulfonylbiphenyl-4-yl)methyl]-7-methyl-imidazo[4,5-b]pyridine


25 100 mg (0.245 mmol) of the compound from Example 30c) are stirred under reflux for 2h with 171 mg (1.24 mmol) of K_2CO_3 , 62 μl (0.62 mmol) of dimethyl dicarbonate and 25 mg of DMAP in 10 ml of diethylene glycol dimethyl ether. The solvent is then distilled off, the residue is treated with an EA/ KH_2PO_4 solution, and the organic phase is separated and washed 2 x with a KH_2PO_4 solution. Drying over Na_2SO_4 , concentration and chromatography on SiO_2 (EA) yielded 44 mg of the title compound.

30












$R_f(\text{SiO}_2, \text{EA}) = 0.15$



MS(FAB): 465 (M+H)

The examples of the formula V shown in the following table were prepared from the building blocks described analogously to the procedures mentioned in Examples 1-33:




Example	R_A	R_B	R_C	Melting Point [°C]	R_f SiO_2	MS(FAB) [M+H]
34	-CH ₃	-H			0.15 (EA)	447
35	-CH ₃	-H			0.17 (EA)	461
36	-CH ₃	H			0.15 (EA)	445
37	-CH ₃	-H			0.3 (EA/MeOH 20:1)	509
38	-CH ₃	-H			0.2 (EA)	432
39	-CH ₃	-H			0.22 (EA)	508
40	-CH ₃	-H			0.2 (EA)	500

Example	R _A	R _B	R _C	Melting Point [°C]	R _f SiO ₂	MS(FAB) [M+H]
41	-CH ₃	-H			0.28 (EA/MeOH 20:1)	474
42	-CH ₃	H			0.16 (EA)	472
43	-CH ₃	H			0.18 (EA)	486
44	-CH ₃	H			0.3 (EA/MeOH 20:1)	446
45	-CH ₃	-CH ₃		120	0.15 (EA)	479
46	-CH ₃	-CH ₃			0.29 (EA)	555
47	-CH ₃	-CH ₃			0.3 (EA)	519
48	-CH ₃	-CH ₃		142	0.28 (EA)	507
49	-CH ₃	-CH ₃		217	0.2 (EA)	488
50	-CH ₃	-CH ₃		205	0.2 (EA)	492
51	-CH ₃	-CH ₃		204	0.2 (EA)	506

Example	R _A	R _B	R _C	Melting Point [°C]	R _i SiO ₂	MS(FAB) [M+H]
52	-CH ₃	-CH ₃		189-191	0,3 (EA)	518
53	-CH ₃	-CH ₃		198	0,2 (EA)	504

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula II



in which the symbols have the following meaning:

- Z(1), Z(2), Z(3) and Z(4) are :
1. $-\text{CH}_2-$,
 2. $-\text{CH}=\text{}$, or
 3. a radical defined in 2., where 1 or 2 methine groups are replaced by nitrogen;

- R(1) is
1. $(\text{C}_1-\text{C}_{10})$ -alkyl,
 2. $(\text{C}_3-\text{C}_{10})$ -alkenyl,
 3. $(\text{C}_3-\text{C}_{10})$ -alkynyl,
 4. (C_3-C_8) -cycloalkyl,
 5. benzyl or
 6. benzyl which is substituted on the phenyl by 1 or 2 identical or different radicals from the series consisting of halogen, (C_1-C_4) -alkoxy and nitro;

R(2) and R(3) are identical or different and are:

1. hydrogen,
2. hydroxyl,
3. halogen,



4. a linear or branched (C₁-C₈)-alkyl radical, unsubstituted or substituted by one or more identical or different substituents from the series consisting of halogen, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylthio and mercapto, or

5. -CO₂R(6);

- R(6) is
1. hydrogen,
 2. (C₁-C₈)-alkyl,
 3. (C₃-C₈)-cycloalkyl,
 4. phenyl,
 5. benzyl or
 6. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine;

L is (C₁-C₃)-alkanediyl;

R(12) and R(13) are identical or different and are

1. hydrogen,
2. halogen,
3. nitro,
4. (C₁-C₄)-alkyl or
5. (C₁-C₂)-alkoxy;

q is zero or 1;

A is either

1. the radical of a heterocycle having 5-10 ring atoms, which can be mono- or bicyclic, and of which up to 9 ring atoms are carbon atoms, which radical is unsubstituted or substituted by up to 3, identical or different radicals R(14) and R(15),

or


2. a biphenyl radical which is substituted by one radical defined in R(15), 14., 15. or 20. below, and q = zero,



- R(14) is
1. (C₁-C₄)-alkyl,
 2. (C₁-C₄)-alkoxy,
 3. cyano,
 4. amino,



5. nitro,
6. fluorine, chlorine or bromine,
7. (C₁-C₄)-heteroaryl-CH₂,
8. (C₁-C₄)-alkanoyloxy,
9. (C₁-C₄)-alkanoyl,
10. benzoyl or
11. tetrazolyl;

- R(15) is 1. (C₁-C₄)-alkyl,
2. ~~(C₈-C₁₂)-aryl~~, (C₆-C₁₂) aryl,
 3. (C₁-C₃)-alkanoyloxy,
 4. (C₁-C₄)-alkoxy,
 5. (C₁-C₉)-heteroaryl,
 6. cyano
 7. nitro,
 8. hydroxyl,
 9. SO₃R(6),
 10. chlorine, bromine,
 11. CO₂R(6),
 12. CO-NH-R(19),
 13. CO-R(20)
 14. SO₂-NR(18)-CO-NR(17)R(16),
 15. SO₂-NR(18)-CO-O-R(17) or SO₂-N(CO-OR(17))₂,
 16. CO-CHR(19)-CO₂H,
 17. (C₁-C₄)-alkyl-CO₂H,
 18. NH-CO-NH-SO₂-CH₂-R(19),






23. R(14) with R(15) together are -CO-NH-SO₂;

R(16) and R(17) are identical or different and are


1. hydrogen,
2. (C₁-C₆)-alkyl,
3. (C₃-C₈)-cycloalkyl,
4. (C₆-C₁₂)-aryl,
5. (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl,
6. 2-pyrimidinyl, 1-piperidinyl, or quinuclidinyl,
7. (C₃-C₆)-alkenoyl,
8. a radical as defined in 4., 5., 6., 9., 14., 15., 16., 18., 19., or 20., substituted by 1 or 2 identical or different radicals from the series consisting of ~~comprising~~ hydroxyl, methoxy, nitro, cyano, CO₂R(6), trifluoromethyl, -NR(25)R(26) and



9. (C₁-C₉)-heteroaryl-(C₁-C₃)-alkyl, where the heteroaryl moiety can be partially or completely hydrogenated,
10. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine,
11. (C₂-C₆)-alkenyl
12. (C₃-C₈)-cycloalkenyl,
13. (C₃-C₈)-cycloalkenyl-(C₁-C₃)-alkyl,
14. (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl,
15. (C₆-C₁₀)-aryl-(C₃-C₆)-alkenyl,



16. (C₁-C₉)-hetaryl-(C₃-C₈)-alkenyl,
17. (C₃-C₈)-alkynyl,
18. (C₆-C₁₀)-aryl-(C₃-C₈)-alkynyl,
19. (C₁-C₉)-hetaryl-(C₃-C₈)-alkynyl,



where R(16) cannot have the meaning of 20. (Stereocenters can be present either in the R- or in the S-configuration).

21. R(16)R(17), together with the nitrogen atom bearing them, form a hetaryl which can also be partially or completely hydrogenated;

R(18) is 1. hydrogen,

R(19) is 1. hydrogen,

2. (C₁-C₆)-alkyl,

3. (C₃-C₈)-cycloalkyl,

4. phenyl or

5. benzyl;

R(20) is 1. hydrogen,


2. (C₁-C₆)-alkyl,

3. (C₃-C₈)-cycloalkyl,

4. phenyl-(CH₂)_q,

5. OR(19),

6. NR(25)R(26) or



R(22) is CO₂R(6) or CH₂CO₂R(6);

D is NR(23), O or CH₂;

R(23) is hydrogen, halogen, (C₁-C₄)-alkyl or (C₁-C₄)-alkoxy;



R(25) and R(26) are identical or different and are

1. hydrogen,
2. (C₁-C₄)-alkyl,
3. phenyl,
4. benzyl or
5. α -methylbenzyl;

T is

1. a single bond,
2. -CO-,
3. -O-,
4. -NH CO-,
5. -O-CH₂-,

and their physiologically tolerable salts; with the proviso that if Z(1), Z(2), Z(3) and Z(4) are -CH=; A is as defined under A2. with q is zero and R(15) is SO₂NH-CO-NHR(16), R(16) cannot be (C₁-C₆)-alkyl; (C₆-C₁₂)-aryl or (C₂-C₆)-alkenyl.

2. A compound of the formula II as claimed in claim 1, in which

Z(1), Z(2) and Z(3) are -CH= and Z(4) is -CH= or N;

R(1) is (C₁-C₇)-alkyl, (C₃-C₇)-alkenyl or (C₃-C₇)-alkynyl;

R(6) is hydrogen or (C₁-C₄)-alkyl;

L is -CH₂-;

q is zero or 1;

A is a radical of benzothiophene, benzofuran, indole, isoindole, indazole, benzimidazole, quinoline, isoquinoline, phthalazine, quinoxaline, quinazoline, cinnoline, benzothiazole, benzothiazole-1, 1-dioxide, coumarin, chroman, benzoxazole, benzisothiazole, benzodiazine, benzotriazole, benzotriazine, benzoxazine, imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazothiazole, pyrazolopyridine, thienopyridine and pyrrolopyrimidine, which radical is unsubstituted or substituted by up to 3 identical or different radicals (R14) and R(15),

R(12) and R(13) are identical or different and are hydrogen or (C₁-C₄)-alkyl;

R(25) and R(26), independently of one another, are hydrogen or (C₁-C₄)-alkyl,



and in which the other substituents and symbols are as defined in claim 1.

3. A compound of the formula II as claimed in claim 1, in which Z(1), Z(2) and Z(3) are -CH= and Z(4) is -CH= or N;

R(1) is (C₁-C₇)-alkyl, (C₃-C₇)-alkenyl or (C₃-C₇)-alkynyl;

R(2) and R(3) are identical or different and are:

1. hydrogen,
2. hydroxyl,
3. halogen,
4. a linear or branched (C₁-C₆)-alkyl radical, unsubstituted or substituted by one or more identical or different substituents from the series ^{consisting of} ~~comprising~~ halogen, hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkylthio and mercapto, or
5. -CO₂R(6);

R(6) is hydrogen or (C₁-C₄)-alkyl;

L is -CH₂-;

q is zero ~~or 1~~ ;

A is a biphenyl radical which is substituted by one radical R(15);


R(15) is SO₂-NH-CO-NR(17)R(16), SO₂-NH-CO-O-R(17) or SO₂-N(CO-OR(17))₂

R(16) and R(17) are identical or different and are


1. hydrogen,
2. (C₁-C₆)-alkyl,
3. (C₃-C₈)-cycloalkyl,
4. phenyl,
5. (C₆-C₁₀)-aryl-(C₁-C₄)-alkyl,
6. 2-pyrimidinyl, 1-piperidinyl, or quinuclidinyl,
7. (C₃-C₆)-alkenoyl,
8. a radical as defined in 4., 5., 6., 9., 14., 15., 16., 18., 19., or 20., substituted by 1 or 2 identical or different radicals from the series ^{consisting of} ~~comprising~~ hydroxyl, methoxy, nitro, cyano, CO₂R(6),



trifluoromethyl, -NR(25)R(26) and



9. (C₁-C₉)-heteroaryl-(C₁-C₃)-alkyl, where the heteroaryl moiety can be partially or completely hydrogenated,
10. the radical defined in 2., in which 1 to all of the hydrogen atoms are substituted by fluorine,
11. (C₂-C₆)-alkenyl,
12. (C₃-C₈)-cycloalkenyl,
13. (C₃-C₈)-cycloalkenyl-(C₁-C₃)-alkyl,
14. (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl,
15. (C₆-C₁₀)-aryl-(C₃-C₆)-alkenyl,
16. (C₁-C₉)-hetaryl-(C₃-C₆)-alkenyl,
17. (C₃-C₆)-alkynyl,
18. (C₆-C₁₀)-aryl-(C₃-C₆)-alkenyl,
19. (C₁-C₉)-hetaryl-(C₃-C₆)-alkynyl,
20. a radical of the formula



where R(16) cannot have the meaning of 20. (Stereocenters can be present either in the R- or in the S-configuration).

21. R(16)R(17), together with the nitrogen atom bearing them, form a hetaryl which can also be partially or completely hydrogenated;

D is NR(23), O or CH₂;


R(23) is hydrogen, halogen, (C₁-C₄)-alkyl or (C₁-C₄)-alkoxy;

R(25) and R(26), independently of one another, are hydrogen or (C₁-C₄)-alkyl, and their physiologically tolerable salts, with the proviso that if Z(4) is -CH= and R(15) is SO₂NH-CO-NHR(16);


R(16) cannot be (C₁-C₆)-alkyl; (C₆-C₁₂)-aryl or (C₂-C₆)-alkenyl.



4. A process for preparing a compound II as claimed in claim 1, which comprises alkylating compounds of the formula III



in which Z(1), Z(2), Z(3), Z(4), R(1), R(2) and R(3) are as defined in claim 1 with compounds of the formula IV



in which L, q, R(12), R(13) and A are as defined in claim 1 and U is a leaving group, optionally removing temporarily introduced protective groups again and optionally converting the compounds of the formula I obtained into their physiologically tolerable salts.

5. A method of preparation of a medicament effective as an angiotensin II receptor antagonist comprising admixing in a pharmacologically effective ratio an effective amount of a compound of the formula I with pharmaceutically acceptable carriers and excipients.

DATED this 9th day of January, 1995.

HOECHST AKTIENGESELLSCHAFT

WATERMARK PATENT & TRADEMARK ATTORNEYS
290 BURWOOD ROAD
HAWTHORN VICTORIA 3122
AUSTRALIA

DOC 40 AU2353392.WPC KJS:KP




ABSTRACT OF THE DISCLOSURE

HOE 91/F 290K

Imidazo-fused iso- and heterocycles, process for their preparation, compositions containing them and their use

A compound of the formula



in which the symbols have the following meaning:

X is a monocyclic radical having 3,4 or 5 ring atoms,
 $R^1, R^2, R^3, R^4, R^{12}$ and R^{13} are, for example, an alkyl radical,

q is zero or 1,

L is, for example, a methylene group and

A is the radical, for example, of a heterocycle

are highly active as antagonists of angiotensin II receptors.

They can be used as pharmaceuticals or diagnostics.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.